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ABSTRACT 	  
HIV-infected persons are more susceptible to TB, and the reasons for this are not 
fully understood. HIV infection leads to CD4+ T cell depletion, compromising 
adaptive immunity to M.tb, however less is known regarding the effect on innate 
immunity. Monocytes play a key role in innate immune defense and are the 
precursors of macrophages. These cells sense pathogens through toll-like receptors 
(TLR), which leads to the release of pro-inflammatory mediators, triggering innate 
and adaptive immune responses to infection, critical events for the control of M.tb. 
The aim of this study was to investigate whether HIV infection induced functional 
defects in monocytes, impairing their ability to respond to M.tb. The focus was on 
TLR functioning in monocytes, by examining whether infection with HIV altered 
cytokine production in response to TLR stimulation. The hypothesis was that co-
infection with HIV may lead to defective TLR responses to mycobacterial TLR 
stimuli. The rationale was that sustained stimulation of HIV-responsive TLR may 
influence how monocytes respond to mycobacteria-encoded TLR ligands. 
 
Whole blood was obtained from 20 HIV-infected and 18 HIV-uninfected individuals 
with CD4 counts >400 cells/mm3 and antiretroviral therapy naïve. A multiparameter 
flow cytometry panel was developed and used to identify monocytes using 
phenotypic markers CD14 and HLA-DR, and to measure the capacity of monocytes 
to produce the cytokines IL-1β, IL-6 and TNF-α, upon stimulation with 
mycobacteria-derived TLR stimuli, mycobacterial lipoarabinomannan (LAM, a 
TLR2 ligand), M.tb purified protein derivative (PPD, which stimulates TLR1, 2, 4 
and 6), live Bacillus Calmette Guérin (BCG, a stimuli for TLR1, 2, 4, 6 and 9), as 
well as lipopolysaccharide (LPS, a TLR4 agonist from gram-negative bacteria).  
 
Monocytes differed in their ability to respond to the different TLR stimuli in healthy, 
HIV-uninfected individuals. BCG induced the most robust response, with total 
cytokine production detected at a median of 83.2% of monocytes (IQR, 73-85%), 
followed by LAM, LPS and PPD (median 64.1, 45.4 and 8.8%, respectively). 
Monocytes produced mainly IL-1β and IL-6, with fewer producing TNF-α in 
	   x	  
response to all the TLR stimuli. Considerable heterogeneity was observed among the 
donors in response to LAM and LPS. When monocyte cytokine responses were 
compared between the HIV-infected and uninfected groups, there were no significant 
differences to LAM, BCG or PPD stimulation. Analysis of the frequency of total 
cytokine production, individual cytokine production, expression levels of cytokines 
(median fluorescent intensity) as well as polyfunctional capacity of monocytes 
revealed that HIV infection did not alter the cytokine response to these three 
mycobacteria-derived stimuli. In contrast, in response to LPS, total cytokine 
production was significantly enhanced in the HIV-infected group (p=0.002), with the 
frequency of IL-1β+ (p=0.016), IL-6+ (p=0.003) and TNF-α+ (p=0.009) monocytes 
significantly increased in this group compared to HIV-uninfected individuals. 
However, this increase in monocyte response was not related to HIV viral load or 
CD4 T cell count. In addition, the HIV-infected group displayed a significantly 
greater proportion of monocytes producing three cytokines simultaneously (p=0.041) 
in response to LPS. HIV-infected individuals showed significantly reduced 
frequencies of monocytes compared to uninfected individuals (p=0.0328), but this 
did not associate with HIV viral load or CD4 T cell count. However, no difference in 
the expression level of CD14 was observed between the two groups. Upon 
stimulation, the frequency of CD14+ monocytes reduced in response to LAM, BCG 
and LPS (p<0.01, p<0.01, p<0.001), likely due to CD14 shedding. In addition, a 
significant reduction in the expression levels of CD14 on monocytes was observed in 
response to all the TLR stimuli (p<0.001). Interestingly, HIV infection altered the 
degree of CD14 shedding in response to the TLR2 ligand LAM, and the TLR4 
ligand, LPS. In HIV-uninfected individuals, there was an inverse correlation between 
the change in the level of CD14 expression on monocytes in LAM, BCG and LPS-
stimulated cultures and cytokine responses to these stimuli (p=0.016, r=-0.56; 
p=0.033, r=-0.505 and p=0.013, r=-0.573 respectively), whilst this relationship was 
disrupted in HIV-infected individuals, where no such correlation was observed.  
 
Overall, these data demonstrate that HIV co-infection does not impair the ability of 
monocytes to secrete key cytokines in response to mycobacteria-derived stimuli, 
although there was evidence of CD14 dysregulation in response to mycobacterial 
LAM in HIV-infected individuals. In contrast, there was enhanced responsiveness of  
	   xi	  
monocytes to LPS stimulation during HIV infection. This may reflect specific TLR4 
cross-talk from ongoing activation of the innate immune system by HIV-encoded 
TLR ligands or by the circulating products of microbial translocation from the gut. 
During HIV infection, monocytes exhibit a differential responsiveness to the degree 
of CD14 shedding, and the association between monocyte cytokine response and the 
extent of CD14 shedding from monocytes is disrupted in these individuals. With LPS 
stimulation, this relationship may be disturbed due to the enhanced monocyte 
cytokine production observed in HIV-infected individuals. However, with LAM 
stimulation, the reduced degree of CD14 loss observed in response to LAM in HIV-
infected individuals might have long-term consequences for cytokine production or 
other functions of monocytes. The results of this study provide further insight into 
how HIV affects innate immunity, which is important for a better understanding of 
how a protective immune response develops against M.tb. 
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1.1  Introduction 
Tuberculosis (TB) remains a huge public health, social and economic burden not only in 
developing countries but also worldwide (Dye et al., 1999). Despite various strategies 
being implemented to address this health challenge, morbidity due to TB still remains 
high (Corbett et al., 2003). Recent global estimates show that around 8.6 million people 
developed TB and 1.3 million died from the disease in 2012 (WHO, 2013a). 
Mycobacterium tuberculosis (M.tb) infects approximately a third of the world’s 
population, but the majority of those infected will remain asymptomatic and can control 
the infection. However, 5-10% of individuals with latent TB infection have a danger of 
reactivation and will develop the active TB disease. HIV has been an important risk 
factor contributing to the reactivation of latent TB (Corbett et al., 2003; Glynn et al., 
2008; Sonnenberg et al., 2005).  Of the 34 million people living with HIV worldwide, 
those individuals infected with latent TB are 21-34 times more likely to develop active 
TB disease than those without HIV (WHO, 2013b), and 75% of the HIV positive TB 
cases are present in Africa (WHO, 2013a; Figure 1.1).   
       
Figure 1.1: Estimated HIV prevalence in individuals newly infected with TB. This map 
shows the global overview of HIV positive TB cases.  In parts of southern Africa, more than 
50% of TB cases are co-infected with HIV. (Taken from Global Tuberculosis Report 2013- 
WHO, 2013a). 
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These alarming trends make it important to understand the mechanisms that lead from 
latent TB infection to active TB disease in HIV-infected individuals, which may give 
insights into combating the disease. HIV infection impairs the ability of the host to 
control M.tb infection by affecting the innate and adaptive immune system (as reviewed 
by Walker et al., 2013; Diedrich & Flynn, 2011). Many studies have focused on how 
CD4 T cell depletion by HIV compromises the adaptive immune response to M.tb. 
Comparatively less is known regarding the effects of HIV on innate immunity to M.tb. 
The focus of this thesis is innate immune dysfunction during HIV infection and the 
consequences for TB. This chapter discusses the innate immune defects caused by HIV 
infection that may lead to the increased susceptibility of HIV-infected individuals to 
develop TB. It specifically focuses on how HIV affects the Toll-like receptor (TLR) 
functioning of innate cells and how this may impact the ability of these cells to respond 
to M.tb.  	  
1.2  Mycobacterium tuberculosis (M.tb) infection 
TB infection is caused by the intracellular pathogen M.tb, which is transmitted through 
the respiratory route (as reviewed by Philips & Ernst, 2012). The infection is initiated by 
the inhalation of aerosol droplets containing a few bacilli. Once these bacilli reach the 
lungs, the host mounts an immune response to the pathogen. Classically, TB was 
understood to exist as either an active disease or latent infection. However, growing 
evidence suggests a new paradigm of TB infection where latent TB exists as a 
heterogeneous spectrum of clinical states (as reviewed by Lin & Flynn, 2010). On one 
side of the spectrum, M.tb infection can be cleared through an effective innate immune 
response without the need for T cell priming, and on the other end, active disease 
develops due to a failure of innate and/or adaptive immunity to M.tb. In between the two 
ends exists the latent state, where a range of immune response can control M.tb to 
different degrees (as reviewed by Walker et al., 2013). Individuals remain latently 
infected and are susceptible to disease reactivation when their immune system is 
compromised, as observed during HIV infection. In the following section, components 
of the immune response that are essential for controlling M.tb infection will be 
reviewed.  
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1.3  Immune response to M.tb 
The immune response to M.tb consists of the innate and the adaptive arm, that work in 
concert to bring about an appropriate host response to M.tb (as reviewed by Hoebe et al., 
2004). However, the exact immune mechanisms mediated against this pathogen are not 
completely understood. Various innate immune cells and mediators are involved, and 
together with the cellular adaptive response, ensure that an effective response is mounted 
against M.tb. Since this study focuses on how the innate immune response to M.tb is 
affected by HIV, this section will mostly focus on this aspect of immunity to TB, 
followed by a brief overview of how adaptive immunity is also involved. 
 
1.3.1  Innate immunity to M.tb 
Innate immune cells form the first line of defense against M.tb infection and play an 
important role in immune recognition of M.tb. The innate immune response is initiated 
by pattern recognition of microbial structures called pathogen-associated molecular 
patterns (PAMPs; as reviewed by Akira et al., 2001). This is mediated by germline-
encoded receptors referred to as pattern recognition receptors (PRRs) that are expressed 
by immune cells. Upon recognition of M.tb cell wall components, a series of signaling 
pathways become activated, that result into the release of various pro-inflammatory 
mediators that are important to mount an effective immune response to M.tb. 
 
1.3.2  Role of innate immune cells in M.tb infection 
The first cells in the airways and lungs that encounter M.tb are alveolar macrophages 
(AMs), which are central in innate pulmonary defense, being the major cell type 
responsible for killing M.tb (as reviewed by Sasindran & Torrelles, 2011). They 
phagocytose M.tb through receptors such as the, mannose, complement and scavenger 
receptors (as reviewed by Ernst, 1998; Hirsch et al., 1994). These cells are also central 
to lymphocyte recruitment and activation and in orchestrating the granulomatous 
response to contain M.tb (as reviewed by Urdahl et al., 2011). However, AMs are also 
the target cell for M.tb, and can support the replication and long-term persistence of 
bacteria, as M.tb can interfere with antimicrobial mechanisms of macrophages such as 
phagolysosome fusion and production of reactive nitrogen intermediates (as reviewed by 
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Flynn & Chan, 2003 and Pieters, 2008). Recent evidence showed that neutrophils are 
also an important target of M.tb during active pulmonary TB (Eum et al., 2010). 
Mycobacteria that escape the destruction by host phagocytes replicate and lead to the 
disruption of the function of these innate cells.  
 
Detection of M.tb by the PRRs on macrophages induces a local pro-inflammatory 
response that leads to the recruitment of more macrophages and other innate cells such 
as neutrophils, dendritic cells (DC) and monocytes to the site of infection to mount an 
immediate response to clear the pathogen. The monocytes differentiate into 
macrophages that also ingest M.tb (as reviewed by Crevel et al., 2002). These cells 
accumulate at the site of infection to establish granulomas, which is the hallmark of M.tb 
infection (as reviewed by Ernst, 2012; Figure 1.2). DCs can phagocytose M.tb and 
migrate to the draining lymph nodes where they prime naïve T cells to initiate the 
adaptive immune response (as reviewed by Mortellaro et al., 2009). The granuloma 
helps to contain and inhibit M.tb growth by allowing antigen-specific T cells to activate 
the infected macrophages (as reviewed by Saunders & Cooper, 2000 and Russell, 2007). 
However, granulomas can also lead to tissue destruction where they form caseous 
necrotic centres, and these can liquefy and erode into the bronchus, resulting in active 
TB disease and spreading M.tb into the environment (as reviewed by de Chastellier, 
2008).  
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Figure 1.2: The cellular composition of a granuloma. Phagocytosis of M.tb by alveolar 
macrophages induces a local pro-inflammatory response that leads to the recruitment of more 
macrophages and other innate cells such as neutrophils and dendritic cells to the site of infection. 
These cells accumulate together to establish granulomas. Lymphocytes also populate the 
granulomas after the adaptive immune response is initiated. Granuloma macrophages can fuse 
together to form multinucleated giant cells as depicted in the diagram (Taken from Philips & 
Ernst, 2012). 	  
1.3.3  Recognition of M.tb by pattern recognition receptors (PRRs) 
The innate immune receptors play a role in the early recognition of pathogens and 
triggering an innate immune response. Macrophages and monocytes express a wide 
range of receptors that recognise diverse microbial ligands. M.tb has a complex cell wall 
which can lead to the simultaneous interaction and activation of a range of receptors 
found on the macrophage cell surface, in the phagosome and in the cytosol (as reviewed 
by Ernst, 1998 and Kawai & Akira, 2011; Figure 1.3). These include receptors such as 
TLRs, immunoglobulin Fc receptors (FcR), C-type lectin receptors (CLRs) and 
nucleotide oligomerisation domain (NOD)-like receptors (NLRs; Kang et al., 2005; 
Divangahi et al., 2008; Ferwerda et al., 2005). The CLRs include among others the 
dendritic cell specific intercellular adhesion molecule-3-grabbing non-integrin (DC-
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SIGN) and the mannose receptor (MR). Some of these receptors activate macrophages to 
release cytokines, chemokines and other antimicrobial factors for containing or killing 
M.tb and inducing adaptive immune responses (as reviewed by Kleinnijenhuis et al., 
2011). Other receptors impair activation and allow the entry of M.tb into the cell. This 
review will focus on the role TLRs play in the innate immune response to M.tb.  
 
                  
Figure 1.3: Immune recognition of M.tb by pattern recognition receptors. Mycobacteria can 
be recognised by various pattern recognition receptors (PRRs) found on the cell surface, in the 
phagosome and in the cytosol. The Toll-like receptors (TLRs) involved in recognition of 
mycobacterial components include TLR2, TLR1/2, TLR2/6, TLR4 and TLR9. Upon binding of 
an M.tb ligand to the TLRs, adaptor molecule MyD88, gets recruited and plays a role in 
initiating signaling pathways that lead to the production of a range of pro-inflammatory 
cytokines and chemokines. The complement receptors (CRs), mannose receptors (MRs) and 
scavenger receptors (SRs) are mainly involved in the uptake of M.tb while the cytosolic receptor 
NOD2 interacts with M.tb derived peptidoglycan component muramyl dipepetide (M.tb-MDP). 
Dashed arrow signifies various other signaling molecules involved (Figure adapted from 
Hossain & Norazmi, 2013). 
 	  
M.tb%
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1.3.3.1  Toll-like receptors involved in M.tb recognition 
TLRs are type 1 membrane proteins that have an extracellular domain of leucine-rich 
repeats and a cytoplasmic Toll/IL-1 receptor (TIR) domain (as reviewed by Quesniaux 
et al., 2004). Upon binding of an M.tb ligand to the TLRs, adaptor molecules are 
recruited which trigger downstream signaling cascades that lead to the production of a 
range of pro-inflammatory cytokines and chemokines (as reviewed by Akira et al., 
2001). During M.tb infection, the adaptor protein myeloid differentiation primary 
response protein 88 (MyD88) plays a prominent role in initiating signaling pathways by 
binding to the TIR domain. Subsequently, this results in the phosphorylation and 
activation of downstream molecules such as IL-1 receptor-associated kinases (IRAK), 
TNF receptor-associated factor 6 (TRAF6), TGFβ-activated protein kinase 1 (TAK1), 
and mitogen-activated protein (MAP) kinase (as reviewed by Akira & Takeda, 2004; 
Figure 1.3). This ultimately leads to the nuclear translocation of the transcription factor 
NF-kβ and transcriptional activation of cytokine genes such as TNF-α, IL-1β, IL-6 and 
IL-12 (as reviewed by Akira et al., 2001) that are crucial to eliciting adaptive immunity 
to M.tb. Hence, TLR activation serves as a fundamental link between the innate and 
adaptive immune defense against M.tb and other microbial pathogens. 
 
Innate cells express an array of TLRs, which allow them to sense pathogens, release pro-
inflammatory mediators, and trigger innate and adaptive immune responses to infection 
(Muzio et al., 2000). Among the TLR family, TLR1, 2, 4, 6 and 9 can sense M.tb, and 
have been implicated in the susceptibility or control of M.tb from genetic association 
studies and mouse models  (as reviewed by Casanova & Abel, 2002; Doherty & Arditi, 
2004; Stenger & Modlin, 2002; Krutzik & Modlin, 2004). TLR2 can recognise a range 
of mycobacterial structures such as M.tb hsp65, M.tb hsp70, 19kDa lipoprotein, 
lipoarabinomannan (LAM), components of purified protein derivative (PPD) and 
phosphatidylinositol mannoside (PIM; as reviewed by Doherty & Arditi, 2004). TLR2 
forms heterodimers with TLR1 and TLR6 and can bind specific microbial products (as 
reviewed by Stenger & Modlin, 2002 and Krutzik & Modlin, 2004). TLR1/2 recognises 
triacylated lipoproteins (Kleinnijenhuis et al., 2011; Takeuchi et al., 2002) while 
TLR2/6 recognises the PIM component of soluble tuberculosis factor (STF; Bulut et al., 
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2001). TLR4 recognises a heat labile ligand of mycobacteria (Means et al., 1999a), 
while M.tb DNA containing unmethylated CpG motifs is sensed by TLR9 (as reviewed 
by Doherty & Arditi, 2004). 
 
The outcome of the initial encounter between M.tb and these receptors on 
macrophage/monocytes may ultimately determine the outcome of infection, namely 
clearance, latency or disease. The development of disease may also represent a fine-
tuned balance between protective and pathological immune responses (as reviewed by 
Dorhoi et al., 2011).  
 
1.3.3.2  CD14 and TLR signaling  
TLRs also serve as transmembrane signal transducing protein for the CD14 receptor, a 
membrane glycoprotein found on myeloid cells which serves as an LPS-binding receptor 
(as reviewed by Landmann et al., 2000). It exists as membrane-bound form (mCD14) as 
well as a soluble form (sCD14; Wright et al., 1990). The soluble form plays a role in 
signal activation in cells that lack CD14, such as endothelial and epithelial cells (Yu et 
al., 1998). Plasma LPS-binding protein (LBP), a soluble serum protein, binds to LPS 
and forms a complex with the CD14 receptor, leading to cellular activation. CD14 is a 
glycophosphatidylinositol-linked protein and lacks the transmembrane and intracellular 
domains, and therefore cannot induce signals on its own (as reviewed by Triantafilou & 
Triantafilou, 2002). Thus, TLRs transduce signals for the CD14 receptor, with TLR4 
required for the signaling of LPS. Besides LPS, CD14 also acts as a receptor for 
recognition of other bacterial components, such as LAM from mycobacteria (Savedra et 
al.,1996; Pugin et al., 1994). CD14-mediated signaling by LAM and LPS requires TLR2 
and TLR4, respectively (Means et al., 1999b). Hence, distinct CD14 ligands require 
different TLR proteins for intracellular signaling.  
 
Several mediators can regulate and alter CD14 synthesis and expression on myeloid 
cells upon stimulation. Membrane-bound CD14 is shed from the cell surface to the 
soluble form following activation of monocytes (Bazil & Strominger, 1991). Upon LPS 
stimulation in vitro, CD14 expression on monocytes was found to be decreased after 3-6 
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hours (Landmann et al., 1996). At this point, CD14 mRNA was down regulated and an 
increase in sCD14 was observed. Additional studies demonstrated an increase in serum 
sCD14 levels and decreased CD14 expression on peripheral monocytes during sepsis 
and other disorders (Burgmann et al., 1996; Landmann et al., 1995; Oesterreicher et al., 
1995). Higher sCD14 levels have also been reported in HIV-infected individuals, which 
correlated with disease progression (Lien et al., 1998). This issue is discussed in more 
detail in section 1.5.2.3.  
 
1.3.4  Cytokines and chemokines involved in M.tb infection 
M.tb recognition by phagocytic cells leads to the activation of genes that encode various 
pro- and anti-inflammatory cytokines (Ragno et al., 2001), which recruit cells such as T 
cells, neutrophils, monocytes and natural killer (NK) cells to the site of infection, 
leading to activation of these cells (as reviewed by Cooper et al., 2011; Berrington & 
Hawn, 2007; Flynn & Chan, 2001; Crevel et al., 2002). The cytokines involved in M.tb 
infection include the pro-inflammatory cytokines TNF-α (Flynn et al., 1995), IL-1β 
(Yamada et al., 2000), IL-6 (Ladel et al., 1997), the anti-inflammatory cytokines IL-10 
(North, 1998), the Th1 cytokine IFN-γ (Flynn et al., 1993) and the Th1-inducing 
cytokine IL-12 (Khader et al., 2006). The formation of the granuloma is shaped by the 
induction of these cytokines, which initiate the adaptive immune response to M.tb. 
 
TNF-α is produced by monocytes and macrophages exposed to microbial products from 
M.tb (as reviewed by Berrington & Hawn, 2007). It activates macrophages to kill 
intracellular M.tb and plays a role in the formation of the granuloma (Kaneko et al., 
1999; Roach et al., 2002). Mice deficient in TNF-α or TNF-α receptor had an increased 
susceptibility to TB, and granuloma formation was impaired (Flynn et al., 1995). 
Patients using TNF-α inhibitors were more susceptible to TB disease, indicating that 
TNF-α plays an important role in host defense to M.tb (Keane et al., 2001). However, 
excessive TNF-α production can be detrimental and can cause immunopathology 
(Jacobs et al., 2007). 
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IL-1β is another pro-inflammatory cytokine that is first produced in the cell as an 
inactive precursor form (pro-IL-1β) (as reviewed by Sims & Smith, 2010). This gets 
cleaved to an active form upon stimulation, which is then secreted from the cell. 
Stimulation with M.tb ligands triggers the conversion of pro-IL-1β to IL-1β (as reviewed 
by Berrington & Hawn, 2007). This cytokine acts through the IL-1R type 1 receptor that 
activates the production of other pro-inflammatory cytokines (as reviewed by Sims & 
Smith, 2010). Mice deficient in IL-1β and IL-1α were not able to clear M.tb infection 
and formed larger granulomas than wild type mice (Yamada et al., 2000). 
 
M.tb infection also induces the production of IL-6, which is a potent cytokine that plays 
a role during the early innate response to M.tb before adaptive T cell immunity has fully 
developed (as reviewed by Berrington & Hawn, 2007). In the absence of IL-6, mice had 
an increased M.tb burden in the lungs and decreased IFN-γ production compared to wild 
type controls (Ladel et al., 1997). As for TNF-α, IL-6 may also be harmful, with a role 
in suppressing T cell responses having been reported (Vanheyningen et al., 1997). 
 
IL-12 production in M.tb infection promotes the differentiation of naïve T cells into Th1 
cells by inducing production of IFN-γ (as reviewed by Berrington & Hawn, 2007). Mice 
that were deficient in IL-12 had increased susceptibility to M.tb infection (Cooper et al., 
1997). IL-10 is an immunoregulatory cytokine that suppresses the pro-inflammatory 
response and plays a regulatory role in many infections (de Waal Malefyt et al., 1991; as 
reviewed by Saraiva & O’Garra, 2010). Studies in mice revealed that IL-10 promoted 
TB disease progression and can promote reactivation of TB (Beamer et al., 2008; Turner 
et al., 2002). In humans, polymorphisms in the promoter region of IL-10 gene were 
associated with enhanced production of IL-10 from T cells and monocytes, and these 
polymorphisms have been shown to lead to increased susceptibility to TB (Awomoyi et 
al., 2002; as reviewed by Berrington & Hawn, 2007 and Mege et al., 2006; Turner et al., 
1997). 
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IFN-γ is a crucial cytokine of the Th1 cell response for effective control of M.tb (as 
reviewed by Berrington & Hawn, 2007). It is secreted primarily by CD4+ T cells, CD8+ 
T cells and NK cells, and activates macrophages to release cytokines. In the absence of 
IFN-γ, mice showed disseminated mycobacterial infection and defective macrophage 
activation (Cooper et al., 1993; Flynn et al., 1993). In humans, individuals with 
mutations in IFN-γ receptor genes are more susceptible to infection with M.tb (as 
reviewed by Ottenhoff et al., 1998). 
 
In addition, many other cytokines and mediators have also been implicated in the 
response to M.tb, such as IL-17 (Lockhart et al., 2006; Yoshida et al., 2010), granulysin 
(Dieli et al., 2001; Stenger et al., 1999) and vitamin D (Liu et al., 2007; Nnoaham & 
Clarke, 2008) amongst others, and may play important roles in influencing the outcome 
of M.tb infection.  
 
1.3.5  Adaptive immunity to M.tb 
The best-characterised adaptive response to M.tb is the Th1 immune response, that 
involves CD4+ T cells, CD8+ T cells and cytokines, with CD4+ T cells considered to be 
central for host defense (as reviewed by O’Garra et al., 2013). Memory T cells recruited 
to the lung are stimulated by M.tb antigens presented by macrophages and exert their 
protective effect through the production of cytokines such as IFN-γ, that induce effector 
immune responses in macrophages which help to contain the infection (Cooper et al., 
1993). IFN-γ and TNF-α stimulate antimicrobial functions in infected macrophages, 
leading to intracellular bacterial killing through phagolysosome formation and 
production of reactive nitrogen and oxygen intermediates (as reviewed by O’Garra et al., 
2013). M.tb-specific CD8+ T cells also produce cytokines and can lyse infected 
macrophages (as reviewed by Lazarevic & Flynn, 2002 and Woodworth & Behar, 2006; 
Lewinsohn et al., 2003). The cytokines and chemokines released during infection and 
the host-pathogen interactions will determine whether infection is cleared, controlled or 
whether active TB disease develops (as reviewed by Cooper et al., 2011).   
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1.4  Monocytes 
The studies in this thesis specifically focus on monocytes, the precursors of 
macrophages, and how HIV affects TLR functioning in these cells. Hence, this section 
gives a brief introduction to these innate cells, that will be further elaborated on in the 
subsequent section in the context of HIV infection. 
 
Monocytes are key innate cells that represent approximately 5-10% of peripheral blood 
leukocytes in humans (as reviewed by Tacke & Randolph, 2006). They originate in the 
bone marrow from myeloid precursors and are then released into the blood where they 
circulate with a half-life of about three days.  Monocytes migrate and enter tissues and 
differentiate into antigen presenting cells (APCs) such as macrophages and myeloid DCs 
(as reviewed by Auffray et al., 2009; Krutzik et al., 2005). The recruitment of 
monocytes to sites of infection is facilitated by chemokines such as monocyte 
chemoattractant protein 1 (MCP-1), which is recognised by CCR2, expressed on 
monocytes. Non-haematopoietic bone marrow cells are able to detect TLR ligands in the 
bloodstream during infections and express MCP-1, thereby promoting the entrance of 
monocytes into the circulation (Shi et al., 2011).  
 
The TLRs expressed on monocytes include TLR1, 2, 4, 5, 6, 8 and 9 (Muzio et al., 2000; 
O’Mahony et al., 2008; Juarez et al., 2010; Hornung et al., 2002). Dysregulation of 
pathogen sensing by monocytes may have serious consequences for acquisition of 
opportunistic and other infections, and development of disease. Human blood monocytes 
form a heterogeneous group of cells, and three different subsets have been described 
based on the expression of cell surface markers CD14 and CD16 (the latter, a low 
affinity receptor for IgG; as reviewed by Ziegler-Heitbrock et al., 2010). The 
CD14++CD16- monocyte population is referred to as ‘classical’ monocytes and these 
are the most prevalent subset in blood (as reviewed by Ziegler-Heitbrock, 2000). This 
subset maintains tissue macrophages and DC populations. The CD16+ monocyte 
population represents only 5-10% of the total circulating monocytes and comprise the 
CD14++CD16+ intermediate subset and the CD14+CD16++ non-classical monocyte 
subset. These different subsets of monocytes appear to display distinct functions. The 
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non-classical subset has been shown to have patrolling behavior in vivo; they survey the 
endothelium for signs of inflammation or damage (Cros et al., 2010). The intermediate 
CD14++CD16+ subset is characterised as being ‘pro-inflammatory’, due to enhanced 
production of cytokines (Frankenberger et al., 1996). This subset has higher MHC class 
II expression and greater TNF-α production upon stimulation with LPS or TLR2 ligand, 
Pam3Cys (Belge et al., 2002). The CD16+ monocytes are increased in frequency in 
various diseases such as rheumatoid arthritis, atherosclerosis, sepsis, TB and HIV 
infections, amongst others (as reviewed by Wong et al., 2012 and Ziegler-Heitbrock, 
2007). 
 
1.5  Effect of HIV on the immune response to M.tb 
HIV-infected persons are more susceptible to TB disease, and the reasons for this are not 
fully understood (as reviewed by Diedrich & Flynn, 2011). Evidence from human and 
animal studies have identified aspects of the immune response to M.tb that are targeted 
by HIV. Many studies on HIV/TB co-infection have focused on how HIV affects 
adaptive immune responses to M.tb, and have described defects in M.tb-specific T cell 
responses. There were fewer M.tb specific memory CD4 T cells in the peripheral blood 
of HIV-infected individuals with latent TB infection, indicating that M.tb-specific CD4+ 
T cells are depleted early in HIV infection (Geldmacher et al., 2008, 2010). A recent 
study also demonstrated fewer M.tb-specific CD4+ T cells in the lungs in advanced HIV 
infection (Jambo et al., 2011). Most studies have focused on immune responses to M.tb 
in the blood. However, a better understanding of the effect of HIV on immunity in the 
lungs, the site of TB disease, is required. 
 
In addition to targeting the adaptive immunity, HIV also leads to dysfunction of innate 
responses to M.tb. The following section summarises the literature surrounding the 
defects in innate immunity during HIV infection, specifically focusing on TLR 
functioning of monocytes and macrophages.   
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1.5.1  Alveolar macrophage function 
AMs are the first cells in the lung to encounter M.tb, and play a central role in innate 
immunity to M.tb (as reviewed by Kleinnijenhuis et al., 2011). This section briefly 
highlights studies that have examined defects in AM function during HIV infection, 
which may lead to a deficit in innate immunity and result in the increased susceptibility 
to TB in HIV-infected individuals.  
 
An impairment in TNF-α production from AM has been observed during HIV infection 
or after infecting macrophages with HIV in vitro. Decreased secretion of TNF-α from 
AM in HIV-infected patients on highly active antiretroviral therapy (HAART) was 
observed in response to both TLR2 and TLR4 stimulation, compared to healthy controls 
(Nicol et al., 2008). Decreased expression in TLR1, TLR2 (and to some extent TLR4) 
genes in the AM of HIV-infected patients was also observed, which may explain the 
decreased cytokine production (Nicol et al., 2008). Furthermore, impaired TLR4-
mediated MyD88-dependent signaling was present in AM from HIV-infected 
individuals (Tachado et al., 2010). In vitro infection of AM with HIV, reduced M.tb-
induced apoptosis of macrophages by inducing IL-10, which in turn reduced TNF-α 
production (Patel et al., 2007). Another study showed that HIV Nef protein inhibited 
activation of the TNF-α promoter and affected the stability of TNF-α mRNA, which led 
to a reduced M.tb-induced apoptosis of macrophages (Kumawat et al., 2010). Moreover, 
direct HIV infection of macrophages infected with M.tb also decreased their ability to 
acidify vesicles (Mwandumba et al., 2004). It is likely that there may be both indirect 
effects of HIV infection, as well as direct affects in HIV-infected macrophages, on their 
functioning.  
 
HIV infection of innate cells can alter the manner in which these cells respond to M.tb. 
Some in vitro studies demonstrated that HIV-infection of monocyte-derived 
macrophages (MDM) promoted M.tb growth and reduced the viability of macrophages 
(Imperiali et al., 2001; Pathak et al., 2010). Also, in these HIV/M.tb co-infected 
cultures, viral replication was enhanced and higher levels of pro-inflammatory cytokines 
was observed. It was recently shown that HIV-1 Nef activates the TRAF pathway by 
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interacting with TRAF2, TRAF5 and TRAF6, and favors the replication of HIV in 
macrophages (Khan et al., 2013). In addition, recent evidence demonstrates that HIV 
can evade recognition and sensing by innate receptors and favors its replication in 
macrophages through recruitment of the cofactors cleavage and polyadenylation 
specificity factor subunit 6 (CPSF6) and cyclophilins (Rasaiyaah et al., 2013). However, 
it is important to note that very few macrophages get directly infected with HIV in vivo, 
and it may be more likely that HIV leads to dysfunction of these cells indirectly as a 
result of the inflammatory environment of the lung in HIV co-infection (as reviewed by 
Twigg & Knox, 2007 and Borrow, 2011). In fact, it has been estimated that as few as 3 
per 100,000 AMs contain integrated HIV-1 DNA (Collini et al., 2010; Lewin et al., 
1998). HIV is frequently detected in the lungs of infected individuals and can replicate 
to high levels, however it is likely that the major cellular source of HIV in the lungs are 
the T cells and not the AMs (Wood et al., 2003; Brenchley et al., 2008; Twigg et al., 
2008).    
 
Studying the function of AMs in the context of HIV infection is extremely relevant to 
understanding not only the effect on the control of M.tb but also other bacterial 
pathogens. Ongoing studies in our laboratory are examining the effects of HIV co-
infection on transcriptional profiles of AMs. The study presented in this thesis examined 
the functioning of blood monocytes from HIV-infected and uninfected individuals, thus 
the remainder of this review will be centered on monocytes. 
 
1.5.2  Monocyte function 
Monocytes form a heterogeneous group of cells and play an important role in the 
defense against M.tb (as reviewed by Fenton & Vermeulen, 1996). Their innate ability 
to deal with M.tb determines the outcome of the infection. A few previous studies have 
demonstrated that monocyte function is altered following HIV infection, and this may 
contribute to defects in the ability to respond to co-infections (as reviewed by 
Noursadeghi et al., 2006), such as M.tb. 
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Some mechanisms by which HIV infection may alter monocyte (or macrophage) 
function to the advantage of M.tb include reduced oxidative burst capacity (Spear et al., 
1990; Muller et al., 1990), diminished oxygen radical production (Dobmeyer et al., 
1995), downregulation of receptors for chemotactic ligands that are important for 
monocyte recruitment to site of infection (Wahl et al., 1989), and dysregulation of 
cytokine production such as IL-1β, IL-6 and TNF-α (Tilton et al., 2006; Lathey et al., 
1994).  
 
These studies highlight the interaction between HIV and monocytes, leading to 
functional impairment in their role as innate cells of the immune system. As for 
macrophages, direct effects of HIV infection of monocytes on their function have been 
studied, as well as indirect effects affecting their phenotype and functioning which may 
compromise the innate immune response to M.tb 
 
1.5.2.1  HIV infection of monocytes  
Monocytes are susceptible targets for HIV infection, and function as a reservoir for 
persisting virus even during antiretroviral therapy (as reviewed by Coleman & Wu, 
2009; Sonza et al., 2001). However, they are likely to form only a small reservoir of 
actively replicating virus compared to memory CD4+ T cells, since a very small fraction 
of the monocyte population becomes productively infected. HIV replication appears to 
be restricted in most monocytes due to multiple host factors that hinder viral replication, 
such as high levels of apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-
like 3A and 3G (APOBEC3A, APOBEC3G), amongst others (as reviewed by 
Bergamaschi & Pancino, 2010). Estimates show that <0.1% of monocytes contain HIV-
1 DNA in vivo and this persists despite HAART (Collini et al., 2010; Sonza et al., 
2001). Since the half-life of monocytes is approximately 3 days in vivo (before they 
differentiate into macrophages or DCs in tissues), the HIV detected from blood 
monocytes implies an ongoing renewal of infection in these cells (Zhu, 2002). Infection 
of bone marrow hematopoietic progenitor cells with HIV may keep renewing the viral 
pool by passing the virus to the progeny monocytes (as reviewed by Alexaki & Wigdahl, 
2008).  
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Certain subsets of monocytes may be more permissive to infection than others. Several 
studies have revealed that the CD16+ monocytes are more permissive to HIV infection 
due to higher expression of CD4 and CCR5, the cell entry receptors for HIV, and lower 
restrictive antiviral activity within these cells (Ellery et al., 2007; Han et al., 2009). In 
vitro experiments demonstrated that the CD16+ monocyte subset were more permissive 
to HIV infection compared to other monocyte subsets (Ellery et al., 2007), with 
enhanced viral entry and replication in this subset. Furthermore, HIV DNA was detected 
more readily in the CD16+ monocytes compared with the CD14++CD16- classical 
monocytes isolated from HIV-infected individuals on HAART. However, compared to 
memory CD4+ T cells, the HIV DNA copy number in CD16+ monocytes was 2-fold 
lower, suggesting that monocytes make up a very tiny reservoir for HIV and their 
contribution to the total viral pool is small. However, monocytes may serve to transmit 
the virus to other susceptible cells such as CD4+ T cells when they migrate into tissues 
(Lambotte et al., 2000; Sonza et al., 2001; Zhu et al., 2002).  
 
1.5.2.2  Role of CD16+ monocytes in TB and HIV infection 
Studies in HIV-infected individuals and non-human primate models have revealed 
significant shifts in the different monocyte subsets. The CD14++CD16+ subset expands 
following HIV infection (Thieblemont et al., 1995), and a greater frequency of these 
cells is associated with higher plasma HIV viral loads (Kim et al., 2010; Han et al., 
2009). An increase in CD16+ monocytes has also been reported in TB patients, and this 
was associated with severity of TB disease and higher TNF-α plasma levels (Balboa et 
al., 2011). This subset was less able to differentiate into DCs in vitro and instead 
differentiated into DCs that lacked CD1a and DC-SIGN (Balboa et al., 2013). Since 
monocytes are essential sources of APCs, HIV may interfere with their ability to 
differentiate to DCs, which could in turn compromise the development of effective and 
timely adaptive responses to co-infections such as M.tb.  
 
In HIV-infection, higher levels of IL-23 production by CD16+ monocytes were 
observed upon in vitro stimulation of PBMCs with Escherichia coli compared to HIV-
uninfected individuals (Manuzak et al., 2013). In addition, the frequency of CD16+ 
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TLR4+ monocytes and the expression levels of TLR4 expressed on CD16+ monocytes 
were higher in HIV infection compared to healthy controls, which may be responsible 
for the enhanced IL-23 production. Thus, the stimulation of monocytes by microbial 
products and HIV in vivo, may drive these cells to produce IL-23, a heterodimer 
comprised of IL-12p40 and p19 subunits and activates similar signaling pathways to IL-
12 (as reviewed by Lankford & Frucht, 2003). This cytokine functions in the expansion 
and activation of Th17 cells. These cells have been shown to play an important role in 
M.tb infection and in maintaining the granuloma structure (as reviewed by Khader & 
Cooper, 2008). However, excessive Th17 responses may lead to enhanced IL-17 
production that can cause tissue damage and have detrimental effects in TB disease 
(Cruz et al., 2010; as reviewed by Torrado & Cooper, 2010). Thus, the increased IL-23 
production in HIV infection may impair the Th17 balance in TB co-infection. 
 
In HIV infection, CCL2/MCP-1 (a pro-inflammatory chemokine produced by 
monocytes) may be one of the factors contributing to chronic inflammation and 
immunopathology in HIV (as reviewed by Ansari et al., 2011). Recently, it was shown 
that there was a preferential expansion of the intermediate CD16+ monocyte subset with 
an increased production of pro-inflammatory chemokine CCL2 in HIV-infected 
individuals compared to healthy controls (Ansari et al., 2013). In M.tb infection, 
CCL2/MCP1 leads to the recruitment of lymphocytes and monocytes to the lung that 
may cause increased inflammation (Lin et al., 1998). Indeed, MCP-1 mRNA and protein 
were expressed at higher levels in CD14+ monocytes from patients with active TB 
compared to healthy individuals (Lin et al., 1998). Furthermore, functional 
polymorphisms in the CCL2 promoter were associated with increased susceptibility to 
TB and these patients had elevated amounts of plasma CCL2 and lower IL-12 levels 
(Flores-Villanueva et al., 2005). Hence, the increased monocyte-derived CCL2 during 
HIV infection may favour the development of TB.  
 
Taken together, these data highlight the dramatic effect that HIV infection can have on 
monocyte phenotypic heterogeneity, which may alter the ability of these cells to respond 
to co-infections.  
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1.5.2.3  HIV and innate immune activation 
A range of defects associated with pathogen sensing in monocytes have been described 
in HIV infection. These include altered TLR expression (Heggelund et al., 2004; 
Hernandez et al., 2012), aberrant downstream signaling in response to TLR ligands, and 
changes in TLR ligand responsiveness (Lee et al., 2008; Pathak et al., 2009).  
 
Immune hyperactivation is a characteristic immune pathology of HIV infection and is 
linked to disease progression and pathogenesis (as reviewed by Paiardini & Müller-
Trutwin, 2013). The TLR pathway is thought to contribute to the persistent immune 
activation that is seen in individuals chronically infected with HIV. HIV encodes 
TLR7/8 ligands that can lead to direct activation of a range of immune cells (Chang et 
al., 2012).  Single-stranded (ss) RNA of HIV contains multiple uridine-rich sequences 
that directly stimulated TLR7 and TLR8 on monocytes and DCs to produce pro-
inflammatory cytokines such as IL-6 and TNF-α in a MyD88-dependant manner (Meier 
et al., 2007). This could result in the chronic production of pro-inflammatory cytokines 
and be a major contributor to the generalised immune activation observed in HIV 
infection.   
 
Interestingly, pre-stimulation of monocytes with HIV TLR ligands in vitro, can enhance 
pro-inflammatory cytokine release from monocytes in response to other microbial TLRs, 
including TLR2 and TLR4 (Mureith et al., 2010). The likely explanation for this is the 
significant cross talk that exists between TLRs, where stimulation of one TLR may 
enhance or dampen responses through another TLR (as reviewed by Trinchieri & Sher, 
2007). Studies have shown that the phenomenon of cross-talk can occur between other 
TLRs too, such as TLR2, TLR3, TLR4, TLR7, TLR8 and TLR9 among others (Bagchi 
et al., 2007; Mäkelä et al., 2009; Napolitani et al., 2005; Sato et al., 2000).  Thus, HIV 
infection may directly or indirectly modulate expression and function of a range of 
TLRs, and this could affect the innate sensing of pathogens such as M.tb (Figure 1.4).          
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Figure 1.4: Recognition of M.tb components and HIV ligands by TLRs on monocytes. 
Single-stranded (ss) RNA of HIV contains multiple uridine-rich sequences that stimulate TLR8 
on monocytes. HIV may have indirect effects on monocyte functioning, whereby sustained 
stimulation of HIV-responsive TLRs may influence how monocytes respond to other TLRs, in a 
process termed  “TLR cross talk”. Thus, HIV infection may indirectly modulate expression and 
function of a range of TLRs involved in the innate sensing of M.tb.  	  
Monocytes from HIV-infected individuals showed increased expression of TLR2 
(Heggelund et al., 2004). In addition, in vitro stimulation of monocytes with HIV 
envelope protein gp120 increased the expression of TLR2 on these cells from HIV-
infected patients. These findings were confirmed by another study that examined 
expression patterns of TLR2 and TLR4 on monocytes from HIV-infected individuals 
(Hernandez et al., 2012). There was increased expression of TLR2 in monocytes from 
HIV-infected individuals compared to healthy controls, but no difference was observed 
in the expression pattern of TLR4 (Hernandez et al., 2012). The increase in TLR2 
expression was associated with higher plasma viral load in HIV-infected individuals. 
Moreover, in vitro HIV infection of MDMs from healthy donors resulted in an increased 
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expression of both TLR2 and TLR4 upon stimulation with TLR2 and TLR4 agonists, 
and this led to higher levels of IL-6 and IL-8 production compared to uninfected MDMs. 
Thus, the increase in TLR expression on monocytes during HIV infection can increase 
the pro-inflammatory cytokine production which can play a role in immune activation. 
In line with these data, circulating monocytes in HIV infection had a sustained TLR2 
gene signature (increased expression of genes for pro-inflammatory cytokines and 
chemokines among others) compared to controls, suggesting that monocytes are 
constitutively activated in HIV infection (Gekonge et al., 2012). This constitutively 
activated profile may affect the functioning of monocytes when they are recruited to 
tissues, or their differentiation into macrophages or DCs.  
 
HIV has also been shown to affect TLR9 responses from monocytes. TLR9 is involved 
in the recognition of unmethylated CpG motifs in bacterial DNA (Hemmi et al., 2000). 
Monocytes from HIV-infected individuals demonstrated impaired maturation (reduced 
induction of CD40 and CD83) and interferon α/β responses upon stimulation with CpG 
ODN (a TLR9 agonist) compared to monocytes from uninfected individuals, and the 
defects were related to plasma viral load (Jiang et al., 2005). Hence, HIV can lead to 
TLR9 dysfunction and affect the innate immune function of monocytes to bacterial 
infections (as reviewed by Noursadeghi et al., 2006), including M.tb infection.  
 
A recent genome wide transcriptome analyses of monocytes showed that TLR signaling 
pathways are down-regulated in viremic HIV-infected individuals on HAART, as 
demonstrated by decreased TLR expression, reduced expression of cytokine genes and 
decreased expression of genes encoding MAPK, NF-kβ, JAK-STAT and IRF signaling 
cascades (Wu et al., 2012). However, these pathways were up regulated in non-
progressive antiretroviral therapy (ART) naïve patients, in line with the findings that 
also showed increased TLR expression on monocytes from HIV-infected individuals 
(also ART naïve) (Heggelund et al., 2004; Hernandez et al., 2012). In addition, 
dysregulation of TLR signaling involving IRAK-4 has been described, where it was 
found suppressed in HIV-infected THP-1 cells (Pathak et al., 2009). Another study 
reported dysregulation of the JAK-STAT and MAPK signaling in HIV-infected pediatric 
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patients (Lee et al., 2008). All together, these studies highlight the defects in TLR 
signaling pathways caused by HIV infection which may impair the ability of these innate 
cells to respond to pathogens such as M.tb. 
 
Apart from HIV-encoded TLR ligands, it is hypothesised that microbial translocation 
through the gastrointestinal tract allows components of gut bacteria to enter the blood 
stream, and this may lead to activation of monocytes (Brenchley et al., 2006a, 2006b). 
HIV leads to the depletion of CD4 T cells in the gut early in HIV infection (Brenchley et 
al., 2004). This results in a compromised mucosal barrier that leads to an increase in 
translocation of microbial products into the systemic circulation, such as LPS and 
bacterial DNA that stimulates monocytes to produce cytokines via TLR4 and TLR9 
(Brenchley et al., 2006a; Jiang et al., 2009). Higher levels of sCD14 were associated 
with the increased levels of plasma LPS (Brenchley et al., 2006a). 
 
Interestingly, monocyte activation has been linked to various non-AIDS co-morbidities 
in chronically HIV-infected individuals, such as dementia and cardiovascular disease 
(CVD) (as reviewed by Marchetti et al., 2013). Recently, a study reported that increased 
IL-1β production from monocytes leads to high levels of IL-6 responses (a biomarker of 
CVD) in HIV-infected individuals on ART (Jalbert et al., 2013). This may lead to 
systemic inflammation and increase the risk for all-cause mortality in these individuals. 
Importantly, plasma levels of sCD14 were associated with an increased risk of mortality 
in HIV infection (Sandler et al., 2011).  
 
The scavenger receptor CD163 is expressed by monocytes and macrophages and the 
receptor gets shed as sCD163 upon TLR2, TLR4 or TLR5 activation (Weaver et al., 
2006, 2007). Elevated levels of sCD163 were found in the plasma of HIV-infected 
individuals, which was positively correlated with plasma viral loads and negatively 
correlated with CD4+ T cell counts (Burdo et al., 2011). In addition, the levels of 
sCD163 were positively correlated with the percentage of the intermediate 
CD14++CD16+ monocyte subset. Elevated levels of sCD163 have also been described 
in TB infection, and this was associated with increased mortality in active TB patients 
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(Knudsen et al., 2005). Therefore, the high levels of sCD163 in HIV infection can have 
detrimental effects in M.tb co-infected individuals. 
 
All together, the presence of HIV ligands, particularly ssRNA, a potent activator of 
TLR7/8, in the circulation during chronic infection, together with PAMPs from 
opportunistic pathogens that enter the host due to compromised immune barriers and 
translocation of microbial products from the gastrointestinal tract, may influence 
responses to other TLRs. This may alter monocyte function during co-infection with 
pathogens such as M.tb. 
 
1.6  Aims and objectives of the thesis 
This study sought to understand whether infection with HIV induced functional defects 
in blood monocytes, impairing their ability to respond to mycobacteria. The focus was 
on TLR functioning in monocytes, as these receptors are central in orchestrating a 
protective response to pathogens like M.tb. The specific objective was to examine 
whether infection with HIV altered TLR responsiveness and inflammatory cytokine 
secretion in response to stimulation with mycobacteria-derived TLR ligands. 
The hypothesis was that co-infection with HIV may lead to defective TLR responses to 
mycobacterial TLR stimuli. The rationale behind this was that sustained stimulation of 
HIV-responsive TLR may influence how monocytes respond to mycobacteria-encoded 
TLR ligands. 
 
Investigating how HIV infection affects innate immunity to M.tb may be important for 
understanding why HIV-infected individuals are more susceptible to TB. Much remains 
to be learnt about what constitutes a protective immune response to M.tb, and how this 
response fails during HIV infection. Understanding the functional defects associated 
with HIV infection may provide insights into how a protective immune response 
develops against M.tb. 
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2.1 Study design  
This was a cross-sectional study in which 20 HIV-infected individuals and 18 HIV-
uninfected individuals were recruited, all with suspected latent TB infection (LTBI). 
Volunteers were recruited from the Ubuntu HIV-TB clinic in Khayelitsha, Cape 
Town for peripheral blood draw after a written informed consent was received from 
all participants. Exclusion criteria for the study included antiretroviral therapy use, 
pregnancy, age <18 years, recent TB disease (within five years prior to enrollment in 
this study), treatment for TB, and any other acute or chronic disease. Age and TB 
history of the participants were collected through a questionnaire. LTBI was 
diagnosed based on the following criteria: no signs or symptoms of active TB disease 
by a screening questionnaire, a positive IFN-γ release assay by a QuantiFERON® 
Gold In-Tube assay that measures M.tb-specific immunity, and no evidence of active 
TB by chest X-ray. Ethical approval for this study was obtained from the Research 
Ethics Committee of the Faculty of Health Sciences, University of Cape Town 
(Reference number 158/2010).  
 
2.2 Determining clinical characteristics of study participants 
2.2.1  QuantiFERON® Gold In-Tube assay 
The QuantiFERON®-TB Gold In-Tube assay (Cellestis Laboratories, USA) is a 
whole blood test for cell-mediated immune responses to M.tb. Blood drawn from the 
participants was collected directly into QuantiFERON® tubes coated with M.tb 
antigens (ESAT-6, CFP-10 and TB 7.7), a mitogen positive control and negative 
control tubes. The tubes were incubated for 24 h at 37°C after which they were 
centrifuged for 7 min at 800 x g. The plasma was then collected and used to perform 
QuantiFERON® enzyme-linked immunosorbent assay (ELISA). A positive test was 
considered as ≥ 0.35IU/ml and ≥ 25% of the Nil value (negative control), whilst a 
negative result was defined as <0.35IU/ml and <25% of the Nil value. If the Nil 
value exceeded 8.0 IU/ml or if the Mitogen minus the Nil was less than 0.5IU/ml, the 
result was considered indeterminate and these individuals were not recruited to the 
study.   
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2.2.2 CD4 count determination 
The absolute CD4 cell count from EDTA treated whole blood was determined by 
using the Flow-CARETM PLG CD4 test (Beckman Coulter, Ireland). Viral load and 
CD4 counts were performed by the National Health Laboratory Service (NHLS) 
(Groote Schuur Hospital). Only individuals with CD4 counts >400 cells/mm3 were 
recruited into the study, since the aim was to study defects in response to 
mycobacteria before profound CD4 depletion. 
 
2.2.3 Viral load determination 
HIV viral load was quantified in the plasma of the HIV-infected participants by 
evaluating HIV RNA copies using an Abbott® m2000 RealTime HIV-1 assay 
(Abbott Laboratories, USA) with a detection limit of 40 copies/ml. 
 
Plasma from whole blood was collected by Ficoll-Hypaque (Sigma-Aldrich, USA) 
density gradient centrifugation. This technique was used to isolate peripheral blood 
mononuclear cells (PBMC) from whole blood collected in acid dextrose (ACD) 
tubes from the participants of this study as part of another ongoing project in the lab. 
The method involves layering blood onto Ficoll, a hydrophilic polymer that produces 
a density gradient for the separation of cells and plasma. Upon centrifugation, 
erythrocytes and granulocytes aggregate and sediment, while mononuclear cells do 
not aggregate and form a layer between the plasma and Ficoll. 
 
Briefly, 15 ml of Ficoll was added to a 50 ml Leucosep tube (Greiner Bio-one, 
Germany) containing a filter disc and centrifuged at 800 x g for 1 min to force the 
Ficoll to settle below the filter disc. About 30 ml of whole blood was then poured 
into the tube on top of the filter disc and centrifuged at 800 x g for 15 min. This 
separated the blood components, such that PBMC formed a white layer between the 
plasma and the Ficoll solution. The plasma formed the top most layer and was 
collected and stored as 2 ml aliquots in -80°C for determination of viral loads in 
HIV-infected individuals. Using a sterile pasteur pipette, the PBMC were carefully 
removed and washed twice with 1X PBS containing 1% FBS and counted to 
determine the cell number and viability. They were then cryopreserved and stored in 
liquid nitrogen for later use. 
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2.3 Blood collection and processing 
Peripheral blood from participants was collected in sterile sodium heparin and ACD 
anti-coagulant vacutainer tubes (BD Biosciences, Plymouth, UK) and processed 
within 4 h of collection.  
2.3.1 Whole blood assays 
Blood collected in sodium heparin tubes were used immediately for whole blood 
assays optimised previously (Shey et al., 2012). Whole blood (500 µl) from HIV-
infected and uninfected individuals were stimulated with the TLR stimuli described 
below and incubated in a water bath at 37°C for 6 h, and after 3 h, the protein 
secretion inhibitor, Brefeldin A (BFA, Sigma-Aldrich, USA) was added at a final 
concentration of 10 µg/ml to inhibit cytokine release from the cells. Unstimulated 
cells were included as negative controls. Cells were then washed, stained with a 
viability dye (‘Vivid’, Molecular Probes, USA), fixed and cryopreserved in liquid 
nitrogen for batch staining at a later time point as described below.  
 
2.3.2 Antigens  
The antigens that were used for monocyte stimulations included mycobacteria-
derived TLR stimuli, namely mycobacterial lipoarabinomannan (LAM, a TLR2 
ligand), M.tb purified protein derivative (PPD, which stimulates TLR1, 2, 4 and 6), 
live Bacille Calmette Guérin (BCG, a stimuli for TLR1, 2, 4, 6 and 9) as well as the 
positive control, lipopolysaccharide (LPS, a TLR4 agonist from gram-negative 
bacteria). Table 2.1 summarises the concentration of each antigen used. 
 
Table 2.1: Summary of antigens used for monocyte stimulation 
Antigen Working 
Concentration 
Supplier 
LAM-MS 25µg/ml Invivogen, USA 
M.tb PPD 20µg/ml Statens Serum Institute, Denmark 
BCG MOI* of 2 Statens Serum Institute, Denmark 
LPS-SM 25ng/ml Invivogen, USA 
*MOI: Multiplicity of infection (Ratio of bacteria to target cells) 
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LAM is a lipoglycan found in the cell wall of mycobacteria (Briken et al., 2004). 
The LAM used in this study was derived from the non-pathogenic Mycobacterium 
smegmatis (LAM-MS), which has phosphoinositol-capped LAM (PILAM) that 
activates TLR2 (Wieland et al., 2004; Underhill et al., 1999).  
 
The PPD used in this study was a tuberculin preparation made from culture filtrates 
of M.tb (Batch RT50). The composition of PPD is not fully understood but it is a 
mixture of various M.tb antigens (Cho et al., 2012). Recent proteomic and 
bioinformatics analysis identified approximately 354 proteins that were present in 
PPD derived from M.tb, having various functions such as metabolism, virulence, 
lipid metabolism and cell processes, amongst others (Prasad et al., 2013). 
 
BCG used in this study was an attenuated Danish strain 1331, of Mycobacterium 
bovis, and is used universally as a vaccine against TB.  Since it is a viable, live 
pathogen, the intact cell wall and bacterial DNA can activate a range of TLRs 
involved in mycobacterial recognition, such as TLR1, 2, 4, 6 and 9, as well as other 
PRRs (Kleinnijenhuis et al., 2011; Quesniaux et al., 2004). 
 
LPS is a lipoglycan and the main component of the gram-negative bacterial outer 
membrane, and activates the innate immune system via the TLR4, leading to the 
production of pro-inflammatory cytokines (Triantafilou & Triantafilou, 2002). The 
LPS used in this study was an ultrapure preparation derived from Salmonella 
Minnesota (LPS-SM).  
 
2.3.3 Cryopreservation of whole blood 
All reagents used for the experiments are outlined in Table 2.2.	   To preserve 
stimulated cells, whole blood was incubated with alternating lysing solution (ALS) to 
lyse red blood cells. Whole blood was transferred into 15 ml tubes containing 5 ml 
(10X the volume of blood) ALS and incubated at room temperature for 10 min. Cells 
were then centrifuged at 400 x g for 10 min at room temperature and the supernatant 
was discarded and the cells were washed twice with 1X PBS. The cells were then 
stained with a viability marker, Vivid, for 20 min at room temperature in the dark.  
Vivid is a fluorescent amine reactive viability dye used to discriminate dead cells 
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from live cells. The cells were then washed and centrifuged twice with 1X PBS and 2 
ml of FACS lysing solution was added to the cells to fix them and lyse any 
remaining red blood cells. The cells were incubated for 10 min at room temperature, 
after which they were centrifuged and washed twice with 1X PBS. Cells were then 
resuspended in cryopreservation solution consisting of 20% DMSO in FBS. The cells 
were then transferred into pre-cooled labeled cryovials (Greiner Bio-one, Germany). 
The cryovials were then placed in pre-cooled Mr. Frosty containers  (Nalgene, USA). 
These containers are filled with isopropanol (Sigma-Aldrich, USA) that allows a 
gradual freezing of cells at a rate of -1°C/min and limits cell death. DMSO helps to 
maintain cell membrane integrity during the freezing process. Mr. Frosty containers 
were stored at -80°C for 24 h, after which the cells were transferred for storage in 
liquid nitrogen until later use. 	  
 
Table 2.2: List of reagents used in the study 
Reagent Constituent Manufacturer 
Foetal Bovine Serum 
(FBS) 
Heat inactivated foetal bovine serum Invitrogen 
Phosphate Buffered Saline 
(1X PBS) 
NaCl, KCl, Na2HPO4, KH2PO4 Sigma-Aldrich 
Alternating Lysing 
Solution 
NH4Cl, KHCO3, Na4EDTA * 
RPMI-1640 Medium 200mM L-Glutamine and 25mM HEPES Sigma Aldrich 
Pencillin (Pen) 5000 units/ml penicillin Invitrogen 
Streptomycin (Strep) 5000 units/ml streptomycin Invitrogen 
R1 1% FBS in RPMI  * 
R10 10% FBS in RPMI * 
Dimethyl sulfoxide 
(DMSO) 
(CH3)2SO Sigma-Aldrich 
Ficoll-Hypaque Ficoll & sodium diatrizoate Sigma-Aldrich 
Freezing media 20% DMSO in FBS * 
FACS lysing solution (1X) <15% formaldehyde, <50% diethylene 
glycol 
BD 
* Prepared in the laboratory 
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2.4. Optimization of polychromatic flow cytometry panel for detecting 
monocyte cytokine responses 
2.4.1 Introduction 
This study sought to understand how infection with HIV might affect blood 
monocytes, in particular their ability to respond to mycobacteria. The specific 
objective was to examine whether infection with HIV altered monocyte cytokine 
responses to mycobacterial-derived TLR stimulation. Polychromatic flow cytometry 
was used to identify monocytes using phenotypic markers and measuring 
intracellular cytokine production. To address the aims of this study, an eight-color 
antibody staining panel was optimised to measure cytokine responses from 
monocytes. This section briefly describes the steps undertaken to develop and 
optimise the monocyte panel.   
 
2.4.2 Selection of markers and fluorochromes for the flow panel 
Several steps were followed to develop the panel. Markers of interest and their 
fluorochromes were chosen according to the instrument used, that is, a four laser BD 
Fortessa, in this study. 
 
2.4.2.1 Selection of markers for identification of monocytes 
Human blood monocytes are divided into three different subsets based on the 
expression of cell surface markers CD14 and CD16, as shown in Figure 2.1 
(Ziegler-Heitbrock et al., 2010). These include the classical monocytes 
(CD14++CD16-), intermediate monocytes (CD14++CD16+) and the non-classical 
monocytes (CD14+CD16++). The intermediate subset have been shown to expand 
during HIV infection as well as during other disease conditions (as reviewed by 
Wong et al., 2012). This subset produces the highest levels of pro-inflammatory 
cytokines and expresses high levels of HLA-DR (Belge et al., 2002). Hence, this 
study sought to investigate whether HIV infection induces functional defects in all 
these three monocyte subsets by measuring production of the cytokines IL-1β, IL-6 
and TNF-α from these cells. The CD14 and CD16 markers were therefore included 
in the panel. The activation marker HLA-DR is necessary to reliably identify 
monocytes, for gating on the monocyte subsets and for excluding HLA-DR negative 
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granulocytes and NK cells that also express CD16 marker, as described previously 
(Abeles et al., 2012; Autissier et al., 2010).  
                                         
Figure 2.1: Monocyte subsets based on expression of CD14 and CD16. Flow cytometry 
dot plot showing the distribution of the classical, intermediate and non-classical monocyte 
subsets. The classical monocytes express high levels of CD14 but no CD16, the intermediate 
monocytes express high levels of CD14 and low CD16, while the non-classical monocytes 
express low CD14 but high CD16 (Taken from Wong et al., 2012). 
 
2.4.2.2 Selection of fluorochromes for the panel 
Antibodies for the panel were selected based on several factors. These included the 
configuration of the Fortessa flow cytometer instrument. The type and number of 
lasers and detectors will determine whether a given fluorochrome will be excited and 
properly detected by the optical system according to the combination of 
fluorochromes used. It is therefore important to have knowledge of the instrument 
and how many lasers and channels are available to know how many and which 
fluorochromes can be included in the panel. The BD Fortessa in our core facility has 
four lasers available and up to eighteen colours can be detected, as shown in Table 
2.3. 
 
In addition, the expression levels of each cell marker, commercial availability of the 
markers, the level of spectral overlap from each fluorochrome are other factors to 
consider for selection of fluorochromes (Mahnke & Roederer, 2007). Those markers 
that were highly expressed were assigned to less bright fluorochromes, while those 
that were expressed at low levels were matched with brighter fluorochromes. The 
brightness of the fluorochromes can be determined based on their staining index. In 
this panel, fluorochromes such as PE, APC and PECy7 which have high staining 
index, were assigned to cytokines IL-1β, IL-6 and TNF-α that are (usually) expressed 
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at lower levels inside the cells compared to other surface markers in the panel. In 
contrast, less bright fluorochromes such as Pacific Blue and Alexafluor700 were 
assigned to highly expressed markers such as CD3 and HLA-DR.  
 
Table 2.3: Configuration of the BD Fortessa showing the different lasers and detectors 
Laser Detector 
name 
Fluorchrome detected Dichroic 
Long Pass 
Filter 
Band Pass 
Filter 
Blue 488nm SSC Side scatter  488/10 
 B710 Cy5.5PerCP 670LP 685/35 
 B515 FITC, Alexa488, GFP, CFSE, 
Oregon Green 
505LP 515/20 
Green 532nm G780 Cy7PE 750LP 780/60 
 G710 Cy5.5PE 685LP 710/50 
 G660 Cy5PE 635LP 670/30 
 G610 Texas Red PE, Texas Red, 
Alexa594 
600LP 610/20 
 G560 PE Empty 585/15 
 Empty na   
 Empty na   
 Empty na   
Red 640nm R780 H7APC, Cy7APC 740LP 780/60 
 R710 Alexa680, 700 685LP 730/45 
 R660 APC, Alexa647 Empty 670/30 
Violet 407nm V800 QD800 750LP 780/60 
 V705 QD705 685LP 705/70 
 V655 QD655 630LP 670/30 
 V605 QD605, 585, BV605 595LP 605/40 
 V585 QD565 556LP 585/42 
 V545 QD545 535LP 560/40 
 V525 AmCyan, QD525, Horizon V500 505LP 525/50 
 V450 PacBlue, Vivid, Horizon V450 Empty 450/50 
 
2.4.2.3 Other considerations 
Other factors that were also considered were the stability of the markers with the 
staining conditions and experimental procedures used in sample preparation. All 
markers in this study were stained intracellularly, as described before (Shey et al., 
2012). Thus, any downregulation of markers such as HLA-DR and CD14 in response 
to stimulation did not compromise the ability to detect monocytes. Also, all 
stimulations were performed on whole blood assays rather than PBMC, to mimic the 
whole blood conditions in vivo. Since the whole blood samples in this study were 
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only stained and analysed in batches at a later time point after blood collection, it 
was necessary to fix the cells to preserve their stability and expression of markers 
(Davis et al., 2011). The panels were therefore tested in the same conditions as the 
final assay as some aspects of experimental procedure may have an impact on 
sensitivity. This section briefly discusses certain markers that were included in the 
panel to increase the accuracy of the results obtained.  
 
Inclusion of a brilliant violet fluorochrome for the CD14 marker: 
Initially, the FITC fluorochrome was assigned to the CD14 marker. However, a clear 
separation from the CD14 negative population was not observed (Figure 2.2) and 
therefore it was necessary to include a brighter fluorochrome for this marker. Since 
monocytes are identified based on their expression of CD14, it was necessary to 
select a fluorochrome that could reliably identify this population to meet the aims of 
this study. Hence, a brilliant violet (BV) dye was assigned to the CD14 marker, since 
BVs have been shown to be extremely bright with excellent signal to noise ratio 
(Chattopadhyay et al., 2012). BVs are a new class of dyes and are excited by the 
violet laser at 405 nm. The BV570 was selected as it emits at 570 nm and can be 
detected by the Fortessa using the 585/42 bandpass filter. With the anti-CD14-
BV570 antibody, improved separation of the CD14 population was observed (Figure 
2.2). 
                                      
Figure 2.2: Staining of whole blood with anti-CD14-FITC or anti-CD14-BV570 
antibody. Gates showing the separation of live CD14+ population from CD14- population 
after staining of whole blood samples with CD14-FITC and CD14-BV570 conjugated 
antibodies.   	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Inclusion of a viability marker and a dump channel: 
The viability marker, Vivid, was used to discriminate between dead and live cells. 
Since cryopreserved whole blood samples were used, it was important to exclude 
dead cells to improve the quality of data obtained in terms of true cytokine 
responses. The viability marker helps to increase the sensitivity for detecting rare 
events such as cytokines, and prevents false positives, as antibody conjugates can 
non-specifically bind to dead cells (Perfetto et al., 2006). 
 
Furthermore, the markers CD19, CD3 and CD56 were all included as part of a dump 
channel to exclude B cells, T cells and natural killer cells. This helped to improve the 
accuracy of the panel in identifying monocytes by excluding background. These 
antibodies were selected for use in the same channel as Vivid (Pacific Blue) so that a 
single channel could be used to exclude all unwanted events. 
 
Inclusion of a granulocyte marker: 
A previous study showed that stimulation of cells with BCG or LPS led to a decrease 
in side scatter fluorescence for granulocytes and an increase for monocytes which 
prevented separation of monocytes from granulocytes using forward and side scatter 
parameters (Shey et al., 2012). Since the CD16 marker is also expressed by 
neutrophils, they may contaminate the CD16+ monocyte subsets. In addition, some 
granulocytes express high levels of HLA-DR, and therefore the granulocyte marker 
CD66a/c/e was also included in the panel to ensure exclusion of all granulocytes 
(Shey et al., 2012; Ziegler-Heitbrock et al., 2010; Figure 2.3). 
 
	   34	  
                                  
Figure 2.3: Flow plots showing the staining of whole blood samples with anti-CD66 
antibody. The anti-CD66 antibody led to the exclusion of a large population of 
granulocytes, which would otherwise have contaminated the CD16+ monocytes in the CD16 
vs. CD14 flow plot.  
 
Table 2.4 summarises the markers and their fluorochromes chosen for the monocyte 
panel. Markers were selected that were bright and had minimal spectral overlap as 
spillover into other detectors can reduce sensitivity of measuring a particular 
fluorescence in those detectors. 
 
Table 2.4: List of antibodies and fluorochromes selected for the monocyte panel 
Antibody Fluorochrome  Clone Cat. # Titer (µl) Manufacturer 
CD14 BV 570 M5E2 301831 0.25 Biolegend 
CD16 Cy5-PE 3G8 302010 0.25 Biolegend 
HLA-DR Alexa700 L243 307626 0.50 Biolegend 
CD66 Alexa488 ASL-32 342306 0.20 Biolegend 
CD3 Pacific Blue UCHT1 300431 0.30 Biolegend 
CD19 Pacific Blue SJ25-C1 MHCD1928 0.625 Invitrogen 
CD56 Pacific Blue MEM 188 304629 0.30 Biolegend 
IL-6 APC MQ2-13A5 561441 2.00 BD 
TNF-α Cy7-PE Mab11 25-7349-41 0.0625 ebioscience 
IL-1β PE AS10 340516 0.25 BD 
Vivid Pacific Blue  1428  Life Technologies 
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2.4.3    Panel development 
All antibodies and the viability dye were titrated to determine their optimal titer that 
provides the best separation and lowest background signal. Antibody panels were 
evaluated with cells incubated with the full panel as well as ones in which each 
antibody was added sequentially. This allowed identification of antibody conjugates 
that reduced sensitivity. The panel was also compared between different donors to 
ensure sensitivity and reliability of the panel. FMO (Fluorescence minus one) 
controls were performed for all antibodies to confirm antibody compatibility and that 
there was no significant fluorescent spillover into other channels.  
 
2.4.3.1 Challenges encountered with the CD16 marker 
The objective of this study was to distinguish between the various monocyte subsets 
in order to investigate the effect of HIV infection on monocyte cytokine responses to 
mycobacterial-derived TLR stimuli. However, when the full monocyte panel was 
stained on whole blood samples, the distribution of monocyte subsets was not 
observed as expected. The CD14+ classical monocytes could be clearly gated, as 
shown in Figure 2.4. However, the two CD16+ subsets could not be discriminated 
but rather a CD14 intermediate population was observed.  
 
 
 
Figure 2.4: Staining of fixed whole blood samples with the monocyte panel. The flow 
plots show the monocyte population after they were gated on singlets, then gated based on 
their size on the forward scatter and side scatter parameters and then live HLA-DR+CD3-
CD19-CD56-CD66-. The CD14 vs. CD16 flow plot shows a clear gate around the CD14+ 
classical monocytes but a gate could not be drawn for the CD16+ monocyte subsets. 
 
This lack of being able to distinguish the monocyte subsets was not due to lack of 
CD16 staining, as running an FMO control for CD16 confirmed that a CD16 
population was present (Figure 2.5). Hence, the CD16 marker could be detected, 
however, the distribution of the monocyte subsets was lost and no clear separation 
between the subsets was observed.  
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Figure 2.5: FMO control for the anti-CD16-Cy5-PE antibody. Cryopreserved whole 
blood was stained with the full monocyte panel as well as one in which the CD16 antibody 
was excluded. All dot plots were gated on live HLA-DR+CD3-CD19-CD56-CD66- cells.  
 
The protocol and reagents used for intracellular staining of samples may affect the 
performance of some antibodies and change the epitope of certain proteins (Berhanu 
et al., 2003). All samples in this study were fixed with an erythrocyte lysing buffer 
(FACS lysing solution) prior to cryopreservation as fixing cells helps to preserve the 
cellular membrane. However, the fixation buffer contains paraformaldehyde that can 
alter the conformation of proteins and modify the epitope structure which can affect 
antibody recognition of its target (Pollice et al., 1992). Fixation has also been shown 
to alter the fluorescence intensity of certain markers (Davis et al., 2011; McCarthy et 
al., 1994; Stewart et al., 2007). Therefore, the effect of fixation on CD16 marker was 
investigated. 
 
To determine the effects of paraformaldehyde fixation on CD16 marker staining, 
fresh PBMC isolated from a donor were stained with antibodies and compared to 
PBMC stained post-fixation with FACS lysing solution and also compared with 
fixed cryopreserved whole blood from the same donor (Figure 2.6). PBMC stained 
without fixation showed a clear distribution of the three monocyte subsets (Figure 
2.6A). However, when the PBMC were stained after fixation with FACS lyse 
solution, the monocyte subset distribution became unclear. This shows that fixation 
had an effect on the resolution of the CD16 marker (Figure 2.6B). With fixed 
cryopreserved whole blood, this distribution was completely lost, indicating that 
some aspects of the whole blood processing and cryopreservation procedure had an 
effect on the CD16 marker (Figure 2.6C). Fixation reduced the staining intensity of 
the CD16 marker such that it led to a diminished resolution between the positive and 
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negative populations, that made discrimination between different subsets challenging 
in fixed whole blood samples. It therefore appears that the monocyte populations are 
best analysed using fresh PBMC or whole blood with minimum processing and not 
using any fixatives in order to ensure that marker changes do not occur. 
 
              
Figure 2.6: Effect of fixation on monocyte subsets distribution. A shows a clear 
distribution of the three monocyte subsets after staining of fresh PBMC without any 
fixatives. B shows that when fresh PBMC are stained with antibodies after fixation with 
FACS lysing solution, the distribution of the monocyte subsets changes considerably and is 
no longer clear. C shows the CD14 vs. CD16 flow plot for fixed cryopreserved whole blood, 
where the monocyte subset distribution is completely lost. All dot plots were gated on live 
HLA-DR+CD3-CD19-CD56- cells. 
 
Due to time constraints, the panel could not be further optimised to test other clones 
of CD16 antibodies that may not be affected by fixation. Thus, this population was 
omitted from analysis due to unreliable staining and difficulty in gating on this 
population. This served as a limitation in this project in studying the three monocyte 
subsets in HIV infection. 
 
2.4.3.2 Fluorescence minus one (FMO) controls 
FMOs are used to determine whether the fluorochromes chosen for a panel can be 
used in combination with one another. In FMO experiments, one antibody is 
removed at a time to assess potential false positives due to fluorochrome interactions, 
spectral overlap, or tandem-dye degradations that could compromise detection in 
large panels (Perfetto et al., 2004).  
  
FMO controls were performed for all antibodies under the same experimental 
conditions as for samples, that is, whole blood that was stimulated for 6 h with the 
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addition of BFA after 3 h, and the samples were then stained with the viability 
marker (Vivid), fixed and cryopreserved. FMO controls for the monocyte panel are 
shown in Figure 2.7. Very low levels of secondary fluorescence were observed in all 
the channels. The highest level of background signal was seen in BV570 channel 
(0.346%). However, this fluorochrome was assigned to the highly expressed marker 
CD14, and thus, the low background fluorescence was considered negligible 
compared to the positively stained population. 
 
                  
Figure 2.7: FMO controls for the monocyte panel. Cryopreserved whole blood was 
stimulated with LPS for 6 h with the addition of BFA after 3 h. Cells were then stained with 
all antibody-fluorochrome conjugates and then each antibody was sequentially removed one 
at a time. All dot plots were gated on live CD3-CD19-CD56- cells. The antibody excluded 
from the full panel is shown for each channel with its corresponding plot of cells stained 
with the full panel. FM: Fluorescence minus.  
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2.4.3.3 Gating strategy 
The gating strategy used for identifying monocytes and detecting cytokine responses 
from monocytes is shown in Figure 2.8. Cells were first gated on time (for all 
lasers), to exclude any artifacts due to inconsistent acquisition, and then gated on 
singlets to exclude large cellular aggregates. Monocytes were then defined based on 
their size and granularity on forward scatter versus side scatter.  Since some of the 
monocytes, such as the intermediate subset CD14+CD16++, are somewhat smaller in 
size than the classical monocytes, they tend to localise in the lymphocyte area and 
therefore the gate was extended to include part of the lymphocyte population 
(Heimbeck et al., 2010). This was followed by gating on all HLA-DR+ cells and 
then the live CD3-CD19-CD56-CD66- were gated to exclude T cells, B cells, NK 
cells and granulocytes, respectively. The CD14+ cells were then gated and the 
cytokines IL-1β, IL-6 and TNF-α were quantified from this subset of cells. Gates 
were set based on the unstimulated control for each participant. The CD16+ subsets 
could not be distinguished clearly as discussed above and were therefore excluded 
from analysis. 
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Figure 2.8: Gating strategy for the monocyte panel. Representative flow cytometry plots 
showing cytokine producing CD14+ monocytes upon stimulation with LAM. Cells were 
gated on time (for all lasers), and then gated on singlets. Monocytes were then defined based 
on their size and granularity on forward scatter versus side scatter. This was followed by 
gating on all HLA-DR+ cells and then the live CD3-CD19-CD56-CD66- were gated to 
exclude T cells, B cells, NK cells and granulocytes, respectively. The CD14+ cells were then 
gated and the cytokines IL-1β, IL-6 and TNF-α were quantified from this subset of cells. 
Gates were set based on the unstimulated control for each participant. 	  
2.5. Determining blood monocyte responses to mycobacterial TLR stimuli 	  
2.5.1 Thawing of cryopreserved samples 
Cryopreserved, stimulated cells, stored in liquid nitrogen were rapidly thawed in 
batches by transferring the vials into a water bath at 37°C. The thawed cells were 
then transferred in a 50 ml centrifuge tube (Sterilin, UK) and 10 ml of pre-warmed 
R1 solution was then added in a drop wise fashion to the thawed cells. The cryovials 
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were rinsed thoroughly to recover all cells and the centrifuge tube was filled up with 
R1 medium to dilute the DMSO, which is toxic to the cells if the temperature 
increases. This was then centrifuged at 400 x g for 10 min. The supernatant was 
discarded and the cell pellet was washed and centrifuged again. The cells were then 
resuspended in 200 µ1 of BD PermWash buffer and transferred onto a 96 well-plate 
for antibody staining as described below. 
 
2.5.2 Antibody staining procedure 
Whole blood cells were stained using a one-step staining method. All reagents used 
for the staining procedure are outlined in Table 2.5. Cells were aliquoted in a V-
bottomed 96-well plate, and centrifuged at 800 x g for 3 min at 4°C. Cells were 
permeabilised by adding 100 µl of PermWash buffer for 20 min in the dark at room 
temperature. The permeabilised cells were then pelleted as before and washed thrice 
prior to staining. Cells were then stained with the antibody master mix prepared in a 
volume of 50 µl for 20 min at room temperature in the dark. The antibody master 
mix consisted of all the markers shown in Table 2.4 above. Stained cells were 
washed thrice with 1X PermWash and centrifuged as before. The cells were then 
fixed with 200 µl of 1X CellFIX (BD Biosciences). The total stained sample volume 
was then acquired on a BD Fortessa flow cytometer.  
 
 
Table 2.5: List of reagents used in intracellular staining 
Reagent Constituent Manufacturer 
FACS wash 
buffer 
1% FBS, 0.001% Sodium azide (Sigma-
Aldrich) 
* 
Perm Wash (1X) FBS, Sodium azide and saponin BD 
CellFIX (1X) 1% w/v formaldehyde and sodium azide BD 
*Prepared in the laboratory 
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2.5.3 Data analysis 
Cells were acquired on a BD Fortessa using FACSDiva software. Compensation and 
data analyses was performed using FlowJo Version 9.4.10 (Tree star Inc, Ashland, 
OR). Additional data analysis was performed using Pestle (provided by Mario 
Roederer, NIH) and Spice software (freely available from 
http://exon.niaid.nih.gov/spice/; Roederer et al., 2011). 
 
2.6 Statistical analyses 
All statistical analyses of data was performed using GraphPad Prism 5 Software (San 
Diego, California, USA). Non-parametric, two-tailed tests were used for all 
comparisons. The Mann-Whitney U test was used to determine any statistical 
differences between the medians of two groups for unmatched data. The Wilcoxin 
matched pairs test was used for matched data. Correlations were performed using 
Spearman Rank correlation test. Assessment of variation between groups was carried 
out through one-way Analysis of Variance (ANOVA) with Dunn’s post-test applied 
to correct for multiple comparisons. A statistical significance was considered for a p-
value less than 0.05. 
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3.1 Introduction 
HIV-infected persons are more susceptible to TB, and the reasons for this are not 
fully understood. Most studies have focused on how HIV infection compromises 
adaptive immunity to M.tb, however less is known regarding the effects on innate 
immunity. Monocytes play a key role in innate immune defense and are the 
precursors of macrophages, which are the main target cells of M.tb. If the ability of 
these cells to respond to M.tb is impaired, it could account for the greater 
susceptibility of HIV-infected individuals to develop TB. One of the ways in which 
these cells respond to M.tb is through TLR stimulation. TLRs are central in 
orchestrating a protective response to M.tb; their activation leads to the release of 
pro-inflammatory mediators, triggering innate and adaptive immune responses to 
infection, critical events for the control of M.tb. This study sought to investigate 
whether HIV infection induced functional defects in monocytes, impairing their 
ability to respond to TLR ligands that are expressed by mycobacteria. The focus was 
on TLR functioning in monocytes, by examining whether infection with HIV altered 
cytokine production in response to TLR stimulation. 
 
In order to examine how HIV affects TLR functioning, a multiparameter flow 
cytometry panel was developed and optimised to characterise cytokine production 
from blood monocytes. Whole blood obtained from 20 HIV-infected and 18 HIV-
uninfected individuals, was stimulated in a short term assay, and intracellular 
cytokine staining of monocytes was performed. The stimuli used included 
mycobacterial lipoarabinomannan (LAM, a TLR2 ligand), M.tb purified protein 
derivative (PPD, which stimulates TLR1, 2, 4 and 6), viable whole Bacille Calmette 
Guérin  (BCG, a stimuli for TLR1, 2, 4, 6 and 9) as well as lipopolysaccharide (LPS, 
a TLR4 agonist from gram negative bacteria), the latter used as a positive control for 
monocyte cytokine responses.  
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3.2 Clinical characteristics of study participants 
To assess the impact of HIV infection on monocyte cytokine responses, blood 
samples were collected from 20 HIV-infected and 18 HIV-uninfected individuals, all 
with suspected latent TB infection in a cross-sectional study approved by the 
University of Cape Town Research Ethics Committee. Only individuals with CD4 
counts >400 cells/mm3 were recruited into the study, since the aim was to study 
defects in the response to mycobacteria before profound CD4 depletion. Exclusion 
criteria for the study included antiretroviral therapy use, pregnancy, age <18 years, 
recent TB disease (within five years prior to enrollment in this study), treatment for 
TB, and any other acute or chronic disease. All participants gave informed consent 
for participation in the study.   
 
Table 3.1 shows the clinical characteristics of the recruited participants. The 
participants were primarily young women; in the HIV-infected group, 80% of the 
participants were females with a median age of 32 (IQR: 29-39), whereas in the 
HIV-uninfected group, 56% of the participants were females with a median age of 22 
(IQR: 19-25). HIV-infected participants were significantly older than HIV-
uninfected participants (p<0.0004). The HIV-infected participants were relatively 
immune competent with a median CD4 count of 581 cells/mm3 (IQR: 530-759), and 
had a wide range of viral loads in their plasma (median, 7787.5 RNA copies/ml; 
IQR: 2677.5-21205.8). 
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Table 3. 1: Clinical characteristics of study participants 
HIV-infected participants (n=20) HIV-uninfected participants (n=18) 
PID Agea Sexb CD4 count 
(cells/mm3) 
Plasma Viral 
load (RNA 
Copies/ml) 
PID Agea Sexb CD4 count 
(cells/mm3) 
1076 25 F 543 908 1001 19 M 631 
1077 47 M 526 28432 1009 21 M 820 
1079 34 F 591 32485 1015 23 M 659 
1080 54 F 774 14100 1024 24 M 939 
1081 37 F 383 3256 1028 44 F 814 
1084 40 F 619 9192 1030 25 F 858 
1086 28 F 1449 4250 1031 19 F 1169 
1119 30 M 545 580150 1032 21 F NAc 
1126 30 F 433 32994 1035 19 F 1459 
1129 31 F 510 4559 1038 18 F 743 
1131 32 M 785 331 1047 26 M 680 
1134 37 F 599 6383 1049 40 F 655 
1137 27 F 560 18797 1052 25 F 1412 
1141 32 F 552 9826 1055 19 M 932 
1142 53 M 441 544849 1057 20 M 871 
1143 26 F 656 618 1058 35 F 866 
1150 26 F 894 311 1060 23 F 902 
1152 30 F 571 9697 1061 21 M 674 
1153 46 F 714 2954     
1154 34 F 988 1848     
Median 32  581 7787.5  22  858 
IQR 29-39  530-759 2677.5-21205.8  19-25  677-936 
ap<0.0004; b % female (HIV+: 80%, HIV-:56%); cNA-data not available  
 
3.3 Effect of TLR stimulation on monocyte cytokine responses  
Monocytes detect microbes through the expression of various pattern recognition 
receptors, such as TLRs (as reviewed by Kleinnijenhuis et al., 2011). To determine 
how monocytes differed in their ability to respond to different TLR stimuli derived 
from mycobacteria, the profiles of cytokine production from monocytes from 18 
healthy, HIV-uninfected individuals were assessed in response to TLR stimulation. 
The TLR2 agonist LAM forms part of the cell wall of mycobacteria (Wieland et al., 
2004). BCG is a viable, live pathogen, and its intact cell wall and bacterial DNA can 
activate a range of TLRs involved in mycobacterial recognition, such as TLR1, 2, 4, 
6 and 9, as well as other PRRs (as reviewed by Hossain & Norazmi, 2013; 
Kleinnijenhuis et al., 2011; Quesniaux et al., 2004). PPD, prepared from culture 
filtrates of M.tb, is a mixture of various mycobacterial peptides and lipoproteins that 
	  	  	  	   46	  
may activate monocytes through TLR1, 2, 4 and 6 (Prasad et al., 2013). LPS is a 
lipoglycan and the main component of the gram-negative bacterial outer membrane, 
and activates innate immune cells via TLR4 (as reviewed by Triantafilou & 
Triantafilou, 2002). 
 
Whole blood was stained ex vivo with phenotypic markers to identify monocytes and 
functional markers to measure cytokine production. The gating strategy is described 
in Chapter 2.  Monocytes were defined based on their size and granularity on 
forward scatter versus side scatter, and then as live, CD3-CD19-CD56-CD66-HLA-
DR+CD14+ cells. The cytokines IL-1β, IL-6 and TNF-α were then measured 
intracellularly from this subset of cells.  
 
3.3.1 Frequency of cytokine responses 
Upon stimulation of monocytes, different stimuli induced markedly different 
monocyte cytokine responses. The representative flow plots in Figure 3.1A 
demonstrate robust production of the cytokines IL-1β, IL-6 and TNF-α above 
background responses from monocytes in response to LAM, BCG, PPD and LPS, 
compared to the unstimulated control. Total cytokine responses (representing 
monocytes secreting any of the three cytokines) are shown in Figure 3.1B. 
Monocytes were most responsive to stimulation with BCG, where cytokine 
production was detected in a median of 83.2% (IQR: 72.9-85.4) of monocytes. This 
was followed by LAM, which induced a median of 64.1% cytokine-positive 
monocytes (IQR: 27.7-73.9), whilst the TLR ligand LPS stimulated nearly 2-fold 
fewer cytokine-producing monocytes (median 45.4%, IQR: 29.3-60.6) compared to 
BCG. PPD was only able stimulate a median of 8.8% (IQR: 2.3-14.4) of monocytes 
(10-fold less) to produce cytokines (Figure 3.1B). When assessing individual 
cytokine responses (IL-1β, IL-6 and TNF-α; Figure 3.1C-E) from monocytes in 
response to these stimuli, the same trend was observed, where BCG was able to 
induce the most robust response for all three cytokines. In general, majority of the 
monocytes produced IL-1β and IL-6, whilst a lower frequency of monocytes 
produced TNF-α. Substantial variability among individuals was observed in their 
production of the three cytokines in response to LAM and LPS. However, this spread 
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among the donors was less striking for BCG or PPD, with the exception of TNF-α 
production, where BCG stimulation did induce a wide range of responses.  
 
3.3.2 Expression level (MFI) of cytokine responses 
The median fluorescence intensity (MFI) of cytokine production signifies the median 
amount of cytokine produced per cell in a population of cells positive for that 
cytokine. Monocytes produced the highest levels of IL-1β, IL-6 and TNF-α in 
response to BCG stimulation, followed by LAM and LPS (Figure 3.2 A-C). 
Cytokine production in response to PPD exhibited the lowest MFI for all three 
cytokines.  
 
3.3.3 Polyfunctional capacity of monocytes 
Next, the polyfunctional capacity of monocytes was compared for the different TLR 
stimuli. Figure 3.3A shows the proportions of monocytes producing one, two or 
three cytokines simultaneously, in response to the different stimuli, LAM, BCG, 
PPD or LPS. A significant difference was observed in the quality of the monocyte 
response between the different stimulations (p=0.0001 between all stimulations, 
except between LAM and LPS where p<0.049; Figure 3.3A). Monocytes displayed 
the greatest polyfunctionality (a higher proportion of three-function monocytes) after 
stimulation with BCG. LPS and LAM elicited nearly equal proportions of the three, 
two and one-cytokine-producing monocytes, however the cytokine profiles were 
significantly different from each other (p<0.049). In contrast, PPD elicited mainly 
monofunctional responses (a higher proportion of one-function monocytes). Figure 
3.3B shows the frequency of the different combinations of cytokine production from 
monocytes. Stimulation with BCG, LAM and LPS stimulated monocytes to either 
produce all three cytokines simultaneously, or dual production of IL-1β and IL-6, or 
the single cytokines IL-1β or IL-6 only. In contrast, PPD induced mainly two 
cytokines, IL-1β and IL-6, and single cytokines, IL-1β or IL-6.  
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Figure 3.1: Cytokine production from stimulated monocytes. A shows representative flow cytometry plots of monocyte cytokine responses from 
whole blood of an HIV-uninfected individual stimulated for 6 h (with the addition of BFA after 3 hours) with LAM, BCG, PPD and LPS, or left 
unstimulated. The numbers on the plots show the frequency of cytokine-producing monocytes. B shows the frequency of the total monocyte 
cytokine response (background-subtracted). C, D and E show the individual cytokines IL-1β, IL-6 and TNF-α, respectively, in response to the 
different stimuli (n=18; background-subtracted). 
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Figure 3. 2: Median fluorescence intensity of cytokine production from monocytes in response to stimulation. The MFI of IL-1β (A), IL-6 (B) 
and TNF-α (C) is shown (lower panel) together with representative histograms (upper panel) from monocytes that were stimulated for 6 h with 
LAM, BCG, PPD and LPS, or left unstimulated (n=18).  
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Figure 3.3: Polyfunctional capacity of monocytes in response to stimulation. A shows 
pie charts representing the proportion of cells producing any one cytokine (green), any two 
cytokines (blue) and any three cytokines (red) simultaneously. B shows the combinations of 
cytokines produced by monocytes in response to the different stimuli, LAM (red), BCG 
(blue), PPD (green) or LPS (orange) (n=18). Statistical comparisons were determined by a 
Mann-Whitney nonparametric t-test. 
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3.4 Effect of HIV infection on cytokine production from blood monocytes 
in response to various TLR stimuli 
HIV may induce defects in monocyte function that could impair their ability to 
respond to M.tb. In an effort to determine whether monocytes from HIV-infected 
individuals respond differently to TLR stimulation compared to uninfected 
individuals, stimulation of whole blood was performed to investigate whether there 
were any functional defects in M.tb-responsive TLRs in monocytes, by measuring 
the production of cytokines from these cells.  
 
3.4.1 LAM 
To investigate the effect of HIV infection on the ability of monocytes to respond to 
LAM, cytokine responses were compared between HIV-infected (n=20) and HIV-
uninfected individuals (n=18). Figure 3.4A shows representative flow plots of 
cytokine production from monocytes when stimulated with LAM or left 
unstimulated. No difference in the cytokine response to LAM (p=0.342) was 
observed between HIV-infected and HIV-uninfected individuals (median 56%, IQR: 
26-66; median 64%, IQR: 28-74 respectively; Figure 3.4B) Similarly, no differences 
were detected in the two groups when individual cytokines IL-1β, IL-6 and TNF-α 
were examined in response to LAM (p=0.357, p=0.373, p=0.174 respectively; 
Figure 3.4C). Considerable variability was observed among the participants in their 
production of the three cytokines in response to LAM. The majority of monocytes 
tended to produce IL-1β and IL-6, and almost 2-fold less TNF-α.  
 
Next, the analysis was extended to assess differences in the functional profiles of 
monocytes between the HIV-infected and uninfected participants. No significant 
difference was detected in the amount of IL-1β, IL-6 or TNF-α produced per 
monocyte between the two groups, however, a trend of higher levels of IL-6 and 
TNF-α from monocytes of HIV-uninfected individuals was observed (p=0.965, 
p=0.066, p=0.066 respectively; Figure 3.5A). Also, comparing the polyfunctional 
capacity of monocytes between HIV-infected and uninfected individuals revealed a 
trend of greater proportion of monocytes in the HIV-infected individuals having the 
capacity to produce only one cytokine in response to LAM (p=0.0928, pie charts in 
Figure 3.5B).  Thus, these results indicate that monocyte cytokine responses to the 
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mycobacteria-derived TLR2 ligand LAM are not impaired in HIV infection. LAM 
stimulated monocytes to produce mainly a combination of IL-1β and IL-6, with a 
lower percentage of monocytes producing all three cytokines or single cytokines 
(Figure 3.5B).  
 
 
Figure 3.4: Effect of HIV on cytokine production by monocytes in response to LAM. A 
shows representative flow cytometry plots of LAM-stimulated and unstimulated monocytes 
from an HIV-uninfected and HIV-infected individual. The numbers denote frequency of 
monocytes producing cytokines. B shows the frequency of total monocyte cytokine 
responses for n=20 HIV-infected and n=18 HIV-uninfected individuals (background 
subtracted). Filled circles represent HIV-infected individuals, while open circles represent 
HIV-uninfected individuals. C shows the frequencies of cells producing IL-1β, IL-6 or TNF-
α (background subtracted). Statistical comparisons were determined by a Mann-Whitney 
nonparametric t-test. 
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Figure 3.5: Effect of HIV on the functional profiles of monocytes in response to LAM. 
A shows MFI (median fluorescent intensity) of IL-1β, IL-6 and TNF-α in monocytes after 
stimulation with LAM, for n=20 HIV-infected and n=18 HIV-uninfected individuals. Filled 
circles represent HIV-infected individuals, while open circles represent HIV-uninfected 
individuals. B shows the polyfunctional capacity of monocytes when stimulated with LAM, 
where the pie charts represent the proportion of cells (of the total response) producing any 
one cytokine (green), any two cytokines (blue) or any three cytokines (red), and the graph 
shows the frequency of responses for combinations of different cytokines. Statistical 
comparisons were determined by a Mann-Whitney nonparametric t-test.  
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3.4.2 BCG 
Monocyte cytokine responses to a viable mycobacteria, BCG, was next compared 
between HIV-infected (n=19) and HIV-uninfected individuals (n=18). One 
individual from the HIV-infected group was excluded due to very few events 
acquired in the sample. Figure 3.6A shows representative flow plots of cytokine 
production from monocytes when stimulated with BCG or left unstimulated. No 
difference in the cytokine response to BCG was detected (p=0.64) between HIV-
infected and uninfected individuals (median 81.5%, IQR: 77-89; median 83.2%, 
IQR: 73-85, respectively; Figure 3.6B). Furthermore, when individual cytokines 
were examined, again no difference was observed in IL-1β, IL-6 or TNF-α 
production in response to BCG (p=0.66, p=0.82, p=0.29 respectively; Figure 3.6C).  
Variability among the donors in their production of TNF-α was observed upon BCG 
stimulation. Also, as with LAM, the majority of monocytes tended to produce IL-1β 
and IL-6, and almost 2-fold less TNF-α in response to BCG. 
 
The functional profile of monocytes was next compared between the HIV-infected 
and uninfected participants. No difference was observed in the amount of IL-1β, IL-6 
or TNF-α produced per monocyte between the two groups (p=0.55, p=0.48, p=0.49 
respectively; Figure 3.7A). Furthermore, no difference was detected in the 
polyfunctional capacity of monocytes between HIV-infected and HIV-uninfected 
individuals (Figure 3.7B). These data suggest that HIV infection does not alter 
monocyte cytokine response to BCG. The majority of the monocytes produced all 
three cytokines simultaneously or a combination of IL-1β and IL-6, whilst a lower 
frequency of monocytes produced either IL-1β or IL-6 only, in response to BCG 
stimulation (Figure 3.7B). 
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Figure 3.6: Effect of HIV on cytokine production by monocytes in response to BCG. A 
shows representative flow cytometry plots of BCG-stimulated and unstimulated monocytes 
from an HIV-uninfected and HIV-infected individual. The numbers denote frequency of 
monocytes producing cytokines. B shows the frequency of the total monocyte cytokine 
response for n=19 HIV-infected and n=18 HIV-uninfected individuals (background 
subtracted). Filled circles represent HIV-infected individuals, while open circles represent 
HIV-uninfected individuals. C shows the frequencies of cells producing IL-1β, IL-6 or TNF-
α (background subtracted). Statistical comparisons were determined by a Mann-Whitney 
nonparametric t-test. 
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Figure 3.7: Effect of HIV on the functional profiles of monocytes in response to BCG. A 
shows MFI (median fluorescent intensity) of IL-1β, IL-6 and TNF-α in monocytes after 
stimulation with BCG, for n=19 HIV-infected and n=18 HIV-uninfected individuals. Filled 
circles represent HIV-infected individuals, while open circles represent HIV-uninfected 
individuals. B shows the polyfunctional capacity of monocytes when stimulated with BCG, 
where the pie charts represent the proportion of cells (of the total response) producing any 
one cytokine (green), any two cytokines (blue) or any three cytokines (red), and the graph 
shows the frequency of responses for combinations of different cytokines. Statistical 
comparisons were determined by a Mann-Whitney nonparametric t-test.  
 
0
20
40
60
80
IL-1!
IL-6
TNF-"
+
+
+ +
+
+
+
+
+
+
+
+
-
-
-
-
- -
-
-
-
%
 N
e
t 
c
y
to
k
in
e
 r
e
s
p
o
n
s
e
 t
o
 B
C
G
HIV: HIV+
HIV+ 
HIV: HIV-
HIV- 
3 
2 
1 
0
5000
10000
15000
20000
25000
BCG
M
F
I
IL-1! IL-6 TNF-"
A 
B 
	  	  	  	   57	  
3.4.3 PPD 
Monocyte cytokine responses to M.tb PPD were compared between HIV-infected 
(n=19) and HIV-uninfected individuals (n=18). One individual from the HIV-
infected group was excluded due to very few events acquired in that sample. Figure 
3.8A shows representative flow cytometry plots of cytokine production from 
monocytes when stimulated with PPD or left unstimulated. No difference in the 
cytokine response to PPD was observed (p=0.29) between HIV-infected and 
uninfected participants (median 11%, IQR: 4.7-17.4; median 9%, IQR: 2.3-14.4, 
respectively; Figure 3.8B). Furthermore, when individual cytokines were assessed, 
no significant difference was observed in IL-1β, IL-6 or TNF-α production in 
response to PPD between the two groups (p=0.35, p=0.52, p=0.64 respectively; 
Figure 3.8C). Once again, considerable variability was observed amongst the donors 
in their production of IL-1β and IL-6 in response to PPD. Also, as with LAM and 
BCG stimulation, the majority of monocytes tended to produce IL-1β and IL-6, with 
very few monocytes producing TNF-α. 
 
The functional profile of monocytes was compared between HIV-infected and 
uninfected participants, and there was no significant difference in the amount of IL-
1β, IL-6 or TNF-α produced per monocyte between the two groups, however, a trend 
of higher levels of IL-6 from monocytes of HIV-uninfected individuals was observed 
(p=0.87, p=0.07, p=0.26 respectively; Figure 3.9A). In addition, no difference in the 
polyfunctional capacity of monocytes was observed between HIV-infected and HIV-
uninfected individuals in response to PPD (Figure 3.9B). These results demonstrate 
that HIV co-infection did not alter the response of monocytes to M.tb PPD. The 
majority of monocytes were monofunctional in response to PPD, and either produced 
IL-6 or IL-1β only, while a lower proportion of monocytes produced a combination 
of IL-1β and IL-6  (Figure 3.9B).  
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Figure 3.8: Effect of HIV on cytokine production by monocytes in response to PPD. A 
shows representative flow cytometry plots of PPD-stimulated and unstimulated monocytes 
from an HIV-uninfected and HIV-infected individual. The numbers denote frequency of 
monocytes producing cytokines. B shows the frequency of total monocyte cytokine response 
for n=19 HIV-infected and n=18 HIV-uninfected individuals (background subtracted). Filled 
circles represent HIV-infected individuals, while open circles represent HIV-uninfected 
individuals. C shows the frequencies of cells producing IL-1β, IL-6 or TNF-α (background 
subtracted). Statistical comparisons were determined by a Mann-Whitney nonparametric t-
test. 
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Figure 3.9: Effect of HIV on the functional profiles of monocytes in response to PPD. A 
shows MFI (median fluorescent intensity) of IL-1β, IL-6 and TNF-α in monocytes after 
stimulation with PPD, for n=19 HIV-infected and n=18 HIV-uninfected individuals. Filled 
circles represent HIV-infected individuals, while open circles represent HIV-uninfected 
individuals. B shows the polyfunctional capacity of monocytes when stimulated with PPD, 
where the pie charts represent the proportion of cells (of the total response) producing any 
one cytokine (green), any two cytokines (blue) or any three cytokines (red), and the graph 
shows the frequency of responses for combinations of different cytokines. Statistical 
comparisons were determined by a Mann-Whitney nonparametric t-test. 
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3.4.4 LPS 
Monocytes can detect the gram-negative bacterial cell wall component LPS, through 
its receptors CD14 and TLR4 (as reviewed by Triantafilou & Triantafilou, 2002). 
LPS was used as a positive control for monocyte cytokine production, as it is not a 
mycobacterial-derived ligand. To examine the impact of HIV infection on the ability 
of monocytes to respond to LPS, cytokine responses were compared between HIV-
infected (n=18) and HIV-uninfected individuals (n=18). Two individuals from the 
HIV-infected group were excluded due to insufficient events acquired in those 
samples. Figure 3.10A shows representative flow plots of cytokine production from 
monocytes when stimulated with LPS or left unstimulated.  In contrast to the results 
with mycobacterial stimulation of monocytes, HIV-infected individuals mounted a 
significantly higher cytokine response to LPS (p=0.002), with a median of 65% 
(IQR: 55.7-72.3) of monocytes producing cytokines, compared to HIV-uninfected 
individuals (median 45%, IQR: 29.3-60.6; Figure 3.10B). Furthermore, when 
individual cytokines were examined, the percentage of IL-1β+, IL-6+ and TNF-α+ 
monocytes were all significantly higher in HIV infection in response to LPS 
(p=0.016, p=0.003, p=0.009, respectively; Figure 3.10C).  Considerable variability 
was observed among the donors in their production of the three cytokines in response 
to LPS. As observed previously with mycobacterial stimuli, the majority of 
monocytes tended to produce IL-1β and IL-6, with fewer monocytes producing TNF-
α. In summary, monocyte responses to LPS stimulation were significantly elevated in 
individuals infected with HIV, compared to HIV-uninfected individuals. 
 
Next, cytokine expression levels and the polyfunctional capacity of monocytes was 
compared between the two groups, to investigate whether any functional differences 
in the monocyte response to LPS was observed in HIV infection. Analysis of 
cytokine MFI showed no difference in the amount of IL-1β, IL-6 or TNF-α produced 
per monocyte between HIV-infected and uninfected individuals (p=0.223, p=0.261, 
p=0.359 respectively; Figure 3.11A). However, comparison of the polyfunctional 
capacity of monocytes revealed differences in the functional profiles of monocyte 
responses in HIV-infected and uninfected individuals. HIV-infected individuals 
displayed a significantly greater proportion of monocytes with the capacity to 
produce all three cytokines simultaneously in response to LPS (p=0.041), and a trend 
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towards a decreased proportion of monocytes producing one cytokine (p=0.085; pie 
charts in Figure 3.11B).  The frequency of monocytes producing all three cytokines, 
or a combination of IL-1β and IL-6, or IL-6 together with TNF-α, was significantly 
greater in HIV-infected individuals (p=0.013, p=0.038 and p=0.011, respectively). 
These data demonstrate that the response of monocytes to the TLR4 ligand LPS was 
significantly enhanced during HIV infection. In contrast, the cytokine response of 
monocytes to LAM, PPD and BCG was similar between HIV-infected and 
uninfected individuals. 
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Figure 3.10: Effect of HIV on cytokine production by monocytes in response to LPS. A 
shows representative flow cytometry plots of LPS-stimulated and unstimulated monocytes 
from an HIV-uninfected and HIV-infected individual. The numbers denote frequency of 
monocytes producing cytokines. B shows the frequency of total monocyte cytokine 
responses for n=18 HIV-infected and n=18 HIV-uninfected individuals (background 
subtracted). Filled circles represent HIV-infected individuals, while open circles represent 
HIV-uninfected individuals. C shows the frequencies of cells producing IL-1β, IL-6 or TNF-
α (background subtracted). Statistical comparisons were determined by a Mann-Whitney 
nonparametric t-test. 
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Figure 3.11: Effect of HIV on the functional profiles of monocytes in response to LPS. 
A shows MFI (median fluorescent intensity) of IL-1β, IL-6 and TNF-α in monocytes after 
stimulation with LPS, for n=18 HIV-infected and n=18 HIV-uninfected individuals. Filled 
circles represent HIV-infected individuals, while open circles represent HIV-uninfected 
individuals. B shows the polyfunctional capacity of monocytes when stimulated with LPS, 
where the pie charts represent the proportion of cells (of the total response) producing any 
one cytokine (green), any two cytokines (blue) or any three cytokines (red), and the graph 
shows the frequency of responses for combinations of different cytokines. Statistical 
comparisons were determined by a Mann-Whitney nonparametric t-test. 
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3.5. Association of monocyte cytokine responses with clinical 
characteristics 
HIV-infected participants exhibited a wide range of cytokine responses, sometimes 
2-fold different between individuals upon stimulation of monocytes with LAM, 
BCG, PPD or LPS.  Since the HIV-infected participants displayed a wide range of 
plasma viral loads (median 3.9, IQR: 3.3-4.4 log RNA copies/ml) and CD4+ T cell 
counts (median 581, IQR: 530-759 cell/mm3; Table 3.1), the relationship between 
monocyte cytokine responses and these clinical characteristics was assessed.  
 
3.5.1 Plasma HIV viral loads 
The relationship between monocyte cytokine responses in HIV-infected individuals 
and their plasma viral loads revealed no correlation following stimulation of 
monocytes with either LAM, BCG, PPD or LPS (p=0.57, r=-0.134; p=0.95, r=-
0.016; p=0.98, r=0.0053; p=0.58, r=-0.141, respectively; Figure 3.12 A-D). When 
assessing the relationship of individual cytokines IL-1β, IL-6 or TNF-α with plasma 
viral loads, again no correlation was found (data not shown). In addition, the 
polyfunctional capacity of monocytes (ability to produce either one, two or three 
cytokines simultaneously) was examined for an association with plasma viral loads 
and demonstrated no correlation (data not shown). Overall, these data show that 
monocyte responses to TLR stimuli in the HIV-infected group were not associated 
with HIV viral loads. 
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Figure 3.12: Relationship between monocyte cytokine responses and plasma viral load. 
Monocyte cytokine production in response to LAM (A), BCG (B), PPD (C) and LPS (D) 
were examined for an association with HIV plasma viral loads in n=18-20 HIV-infected 
individuals. The correlation coefficient (r) and p-values (p) are indicated on the graphs. 
Statistical associations were performed using a two-tailed non-parametric Spearman rank 
correlation.  
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individuals and CD4 T cell count was assessed. These two parameters demonstrated 
no correlation following stimulation of monocytes with either LAM, BCG, PPD or 
LPS (p=0.82, r=-0.954; p=0.95, r=-0.016; p=0.55, r=0.147; p=0.53, r=0.16, 
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Figure 3.13: Relationship between monocyte cytokine responses and CD4+ T cell count. 
Monocyte cytokine production in response to LAM (A), BCG (B), PPD (C) and LPS (D) 
were examined for an association with CD4+ T cell count in n=18-20 HIV-infected 
individuals. The correlation coefficient (r) and p-values (p) are indicated on the graphs. 
Statistical associations were performed using a two-tailed non-parametric Spearman rank 
correlation. 
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assessing the relationship of individual cytokines IL-1β, IL-6 or TNF-α  with age, 
again no correlation was found (data not shown).  
 
These data demonstrate that monocyte cytokine responses to TLR stimuli were not 
affected by the age of the participants. Therefore, any differences in cytokine 
responses observed between the HIV-infected and uninfected groups were not 
influenced by age. Also, the cytokine responses in the HIV-infected individuals were 
not associated with plasma viral loads or CD4+ T cell count.  
 
Figure 3.14: Relationship between monocyte cytokine responses and age. Monocyte 
cytokine production in response to LAM (A), BCG (B), PPD (C) and LPS (D) were 
examined for an association with age in n=18-20 HIV-infected and n=18 HIV-uninfected 
individuals. The correlation coefficient (r) and p-values (p) are indicated on the graphs. 
Filled circles represent HIV-infected individuals, while open circles represent HIV-
uninfected individuals. Statistical associations were performed using a two-tailed non-
parametric Spearman rank correlation. 
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3.6. Effect of HIV on CD14+ frequency and expression levels  
The frequency of classical CD14+ monocytes and CD14 expression levels on 
monocytes were next compared between 20 HIV-infected individuals and 18 HIV-
uninfected individuals.  
 
The frequency of CD14+ monocytes was significantly lower (p=0.0328) in HIV-
infected individuals (median 60%, IQR: 57-70) compared to HIV-uninfected 
individuals (median 70%, IQR 62-74; Figure 3.15A). No difference in CD14 
expression levels on monocytes was observed between the two groups (p=0.77; 
Figure 3.15B). These results indicate that CD14+ monocytes are at a lower 
frequency during HIV infection, consistent with findings from a previous report (Han 
et al., 2009).  
 
               
 
Figure 3.15: CD14+ expression on monocytes in HIV-infected and uninfected 
individuals. A compares the frequency of unstimulated CD14+ monocytes characterised by 
flow cytometry. B shows the expression levels (MFI) of CD14 on monocytes, from n=20 
HIV-infected individuals and n=18 HIV-uninfected individuals.  Filled circles represent 
HIV-infected individuals, while open circles represent HIV-uninfected individuals. 
Statistical comparisons were determined by a Mann-Whitney nonparametric t-test. 
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Next, the relationship between the frequency of CD14+ monocytes and plasma viral 
loads and CD4+ T cell counts was determined. There was no correlation between the 
frequency of CD14+ monocytes and HIV viral loads (p=0.37, r=0.211; Figure 
3.16A) or with CD4 T cell counts (p=0.32, r=-0.232; Figure 3.16B). The association 
between the frequency of CD14+ monocytes with age was also determined, and no 
correlation was found (data not shown). 
              
 
Figure 3.16: Relationship between frequency of monocytes and plasma viral loads and 
CD4+ T cell counts. The frequency of CD14+ monocytes were examined for an association 
with plasma viral loads (A) and CD4+ T Cell count (B) in n=20 HIV-infected individuals. 
The correlation coefficient (r) and p-values (p) are indicated on the graphs. Statistical 
associations were performed using a two-tailed non-parametric Spearman rank correlation.  
 
Overall, these results indicate that there were significantly fewer CD14+ monocytes 
in HIV-infected individuals, and this was not associated with plasma viral loads or 
CD4 T cell count, consistent with findings from a previous report (Han et al., 2009). 
These data demonstrate that HIV may have indirect effects on the frequency of 
classical CD14+ monocytes.  
 
3.7. Loss of CD14 from stimulated monocytes 
CD14, the receptor that is typically used for phenotypic identification of monocytes, 
is a myeloid membrane glycoprotein that serves as a pattern recognition molecule 
and participates in the host defense against various microbial pathogens (as reviewed 
by Antal-Szalmás, 2000; Pugin et al., 1994). Specifically, it acts as a receptor for 
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LPS, LPS-binding protein as well as other host and bacterial components (as 
reviewed by Triantafilou & Triantafilou, 2002). CD14 plays a role as an accessory 
co-receptor not only for TLR4, but also for TLR2. Besides LPS-induced activation of 
TLR4/CD14, other bacterial components such as lipoteichoic acid and mycobacterial 
LAM activate TLR2/CD14 (Schröder et al., 2003; Zhang et al., 1993). In fact, it has 
been demonstrated that LAM acts similarly to LPS in activating monocytes through 
CD14 (Savedra et al., 1996; Yu et al., 1998). Interaction of microbial ligands with 
the TLR-CD14 complex leads to the activation of monocytes and results into the 
production of various pro-inflammatory cytokines (as reviewd by Landmann et al., 
2000). Upon stimulation with these ligands, monocytes shed CD14 from their 
surface as the soluble form of CD14 (sCD14; Bufler et al., 1995; Landmann et al., 
1996; Orr & Tobias, 2000). CD14 shedding is induced as a consequence of 
monocyte activation and serves to down-modulate CD14 on stimulated monocytes 
(Bazil & Strominger, 1991). This may function as a regulatory mechanism to prevent 
an excessive pro-inflammatory response.  
 
3.7.1 Differential loss of CD14 in response to TLR stimulation 
To investigate CD14 expression on monocytes upon activation with different TLR 
stimuli, the loss of CD14 from monocytes was determined from 18 healthy, HIV-
uninfected individuals.  
 
The frequency of CD14+ monocytes in response to different TLR stimuli is shown in 
Figure 3.17A. There was a significant reduction in the frequency of CD14+ 
monocytes after they were stimulated with LAM, BCG and LPS (p<0.01, p<0.01 and 
p<0.001, respectively), although no such reduction was observed for PPD. Since 
intracellular staining was performed to detect CD14, which would have labeled the 
marker both on the surface and intracellularly, the reduced frequency of CD14+ 
monocytes could not be attributed to down-regulation of the CD14 receptor, but was 
likely due to a complete shedding of CD14 from a proportion of monocytes, resulting 
in a lower frequency of CD14+ monocytes compared to the baseline, unstimulated 
control. As a result, the median frequency of the monocyte population was 
significantly reduced, from 70% when left unstimulated to 52% upon stimulation 
with LAM, 47% with BCG and 45% after LPS stimulation. In addition, a significant 
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reduction in the expression levels of CD14 on monocytes, as measured by the MFI, 
was observed upon stimulation with LAM, BCG and LPS (MFI of 7445, 6869 and 
7558, respectively; p<0.001 after adjustment for multiple comparisons, compared to 
the unstimulated sample with an MFI of 10118; Figure 3.17B). This reduction in 
MFI of CD14 indicates partial shedding of CD14 on a proportion of the monocytes. 
These findings indicate that besides LPS, other bacterial cell wall constituents, 
namely LAM and components of BCG, also contribute to the loss of the CD14 
receptor.  
                          
Figure 3.17: CD14 expression on monocytes in response to TLR stimulation. A shows 
the frequency of CD14+ monocyte population and B shows the expression levels (MFI) of 
CD14 on monocytes from n=18 healthy HIV-uninfected individuals upon stimulation with 
LAM, BCG, PPD and LPS, or when left unstimulated. Statistical analyses was performed 
using a one-way ANOVA with Dunn’s correction for multiple comparisons (**p<0.01, 
***p<0.001). 
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3.7.2 Effect of HIV infection on loss of CD14 from monocytes 
To determine whether HIV infection affected the shedding of CD14 from monocytes 
in response to the different TLR stimulations, the frequency and expression levels of 
CD14 on monocytes were compared between 18 HIV-uninfected and 20 HIV-
infected individuals in response to LAM, BCG, PPD and LPS (Figure 3.18A and 
B). The frequency of the CD14+ population was reduced compared to the 
unstimulated baseline sample in the same manner as was observed for HIV-
uninfected individuals in response to LAM, BCG and LPS stimulation (HIV-: 
p=0.0014, HIV+: p=0.0018; HIV-: p=0.0003, HIV+: p=0.0001; HIV-: p=0.0002, 
HIV+: p=0.0002, respectively). Similarly, as for HIV-uninfected individuals, no 
significant reduction in the frequency of the CD14 population was observed in 
response to PPD in HIV-infected individuals. Since PPD activated monocytes to the 
lowest levels compared to the other stimuli (as measured by the cytokine production 
from monocytes, described previously), CD14 shedding may only be occurring at 
very low levels.  
 
The expression level of CD14 on monocytes from HIV-uninfected individuals 
(Figure 3.19A) and HIV-infected individuals (Figure 3.19B) in response to the four 
stimuli was investigated. Again, as with the frequency of the CD14 population, a 
reduction in the MFI of CD14 was observed in HIV-infected individuals, as for HIV-
uninfected individuals. The CD14 expression levels were significantly reduced 
compared to the unstimulated sample in response to all the TLR stimuli, namely 
LAM, BCG, PPD and LPS (HIV-: p=0.0002, HIV+: p<0.0001; HIV-: p=0.0003, 
HIV+: p=0.0001; HIV-: p=0.0002, HIV+: p=0.0002; HIV-: p=0.0002, HIV+: 
p=0.0002, respectively). These findings indicate that CD14 is shed partially from 
monocytes, in both HIV-infected and uninfected individuals.  
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Figure 3.18: Frequency of CD14 monocytes in HIV-infected and uninfected individuals 
in response to TLR stimulation. The reduction in the frequency of CD14+ monocyte 
population was determined for n=18 HIV-uninfected (A) and n=18-20 HIV-infected 
individuals (B) in response to LAM, BCG, PPD and LPS.  Filled circles represent HIV-
infected individuals while open circles represent HIV-uninfected individuals. Statistical 
comparisons were determined by Wilcoxon non-parametric matched pairs test.  
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Figure 3.19: Expression levels of CD14 on monocytes in HIV-infected and uninfected 
individuals in response to TLR stimulation. The expression levels of CD14 (MFI) on 
monocytes was determined for n=18 HIV-uninfected (A) and n=18-20 HIV-infected 
individuals (B) in response to LAM, BCG, PPD and LPS.  Filled circles represent HIV-
infected individuals while open circles represent HIV-uninfected individuals. Statistical 
comparisons were determined by Wilcoxon non-parametric matched pairs test.  
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which a change would be considered significant; a change below 0.8 would indicate 
more than 20% loss in CD14, while a fold change greater than 1.2 would indicate 
more than 20% increase in CD14 on monocytes. 
 
When the data were expressed in this way, the fold change in CD14 frequency 
(Figure 3.20A) and expression levels (Figure 3.20B) was <1 for all stimuli except 
for the frequency of CD14+ monocytes after PPD stimulation, consistent with the 
previous data (median CD14% loss: HIV+: 0%, HIV-:0%).  Interestingly, 
differences emerged in the degree of CD14 loss to different stimuli between HIV-
infected and uninfected individuals that were not apparent in the previous analyses. 
Although there were no significant differences between the groups in the degree of 
CD14 loss (either as frequency or MFI) for BCG and PPD, there was a trend towards 
differences in the CD14 loss for LAM and LPS (Figure 3.20A and B). HIV-infected 
individuals had a lower fold change loss in frequency of CD14+ monocyte 
population in response to LAM compared to HIV-uninfected individuals (p=0.0928; 
Figure 3.20A). Two-thirds of the HIV-uninfected participants demonstrated a 
significant (>20%) loss in frequency of CD14+ monocytes, while only 25% of the 
HIV-infected individuals showed a significant loss in CD14+ frequency in response 
to LAM. The same trend was also observed with the fold change in CD14 expression 
(MFI) between the two groups in response to LAM (Figure 3.20B). HIV-infected 
individuals showed a trend of reduced fold change in loss of CD14 expression on 
monocytes when compared to HIV-uninfected individuals (p=0.105). Again, almost 
80% of the HIV-uninfected individuals but only 50% of the HIV-infected individuals 
exhibited a significant loss in CD14 expression. These findings suggest that during 
HIV infection, CD14 shedding from monocytes in response to the TLR2 ligand, 
LAM, is dysregulated. 
 
In contrast to LAM, a trend towards greater loss in the frequency of the CD14+ 
monocyte population in response to LPS was observed in HIV-infected individuals 
compared to HIV-uninfected individuals (p=0.0967; Figure 3.20A), although, no 
difference was observed in the fold change in MFI of CD14 on monocytes between 
the two groups (Figure 3.20B). Monocytes from majority of the participants in the 
two groups showed a significant loss in CD14 expression in response to LPS 
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(CD14%: HIV+: 94%, HIV-: 83%; CD14 MFI: HIV+: 72%, HIV-: 61%). This 
trend of a greater loss in frequency of CD14 during HIV infection (implying more 
shedding in response to LPS stimulation) may be a consequence of the heightened 
monocyte activation, as measured by the enhanced cytokine production from 
monocytes upon LPS stimulation in HIV-infected individuals, reported above.  
Overall, these findings indicate that HIV infection differentially alters the degree of 
CD14 shedding in response to the mycobacterial TLR2 ligand LAM, and the TLR4 
ligand, LPS. 
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Figure 3.20: Change in CD14 expression in HIV-infected and uninfected individuals in 
response to TLR stimulation. A shows the fold change in frequency of CD14+ monocytes 
and B shows the fold change in CD14 expression levels (MFI) on monocytes from n=18-20 
HIV-infected and n=18 uninfected individuals, in response to LAM, BCG, PPD and LPS. 
The solid line represents a fold change of 1 (i.e. no change) and the dashed lines represent a 
20% change threshold. Filled circles represent HIV-infected individuals while open circles 
represent HIV-uninfected individuals. Statistical comparisons were determined by a Mann-
Whitney nonparametric t-test. 	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investigated, to determine whether cytokine production was related to the degree of 
shedding of CD14 upon TLR stimulation (Figure 3.21). Association between 
monocyte cytokine production and changes in the levels of CD14 expression on 
monocytes in response to TLR stimuli revealed that there was a significant inverse 
correlation in HIV-uninfected individuals between the net total cytokine production 
from monocytes and the change in the level of CD14 expression on monocytes in 
response to LAM, BCG and LPS (p=0.016, r=-0.56; p=0.033, r=-0.505; and p=0.013, 
r=-0.573, respectively; Figure 3.21A, B, D). These results indicate that more 
cytokine production from monocytes was associated with a greater loss of CD14 
expression on monocytes in response to LAM, BCG and LPS. In contrast, this 
relationship was disrupted in HIV-infected individuals, where no such correlation 
was observed between the monocyte cytokine response and change in CD14 
expression when monocytes were stimulated with LAM, BCG or LPS (p=0.094, r=-
0.385; p=0.797, r=-0.063; p=0.372, r=-0.224, respectively; Figure 3.21A, B, D). 
Consistent with the previous data, for PPD, there was no association between 
cytokine response and change in CD14 expression for HIV-infected or uninfected 
individuals (Figure 3.21C).  
 
Taken together, these results suggest that during HIV infection, monocytes exhibit a 
differential responsiveness to the degree of CD14 shedding, and the association 
between monocyte cytokine response and the extent of CD14 shedding from 
monocytes is disrupted in these individuals. With LPS stimulation, greater CD14 
shedding in HIV infection is likely linked to the enhanced cytokine production 
observed in these individuals compared to HIV-uninfected individuals. The altered 
degree of CD14 shedding observed in response to mycobacterial LAM (and to a 
certain extent to BCG) reveals an effect of HIV on monocytes, even though no 
differences in cytokine production were observed between HIV-infected and 
uninfected individuals in the short term assays performed in this study. This lack of 
CD14 loss in response to TLR2 stimulation may have implications for the 
functioning of monocytes and control of co-infections such as M.tb. The mechanisms 
associated with CD14 modulation by HIV require further investigation.  
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Figure 3.21: Relationship between monocyte cytokine responses and change in CD14 
expression on monocytes upon TLR stimulation. The association between the net total 
cytokine production from monocytes and fold change in CD14 MFI in response to LAM (A), 
BCG (B), PPD (C) and LPS (D) was determined in n=18-20 HIV-infected individuals and 
n=18 HIV-uninfected individuals. Filled circles represent HIV-infected individuals while 
open circles represent HIV-uninfected individuals. The correlation coefficient (r) and p-
values (p) are indicated on the graph. Significant correlations are indicated in red. Statistical 
associations were performed using a two-tailed non-parametric Spearman rank correlation.  
 
3.8 Summary 
The overall aim of this study was to investigate whether infection with HIV induced 
defects in monocytes, which impaired their ability to respond to M.tb. The focus was 
on TLR responses by monocytes, by determining whether cytokine production in 
response to mycobacteria-derived TLR ligands differed in HIV-infected individuals. 
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A multiparameter flow cytometry panel was developed and optimised to characterise 
cytokine production from CD14+ monocytes in response to TLR stimuli, LAM, 
BCG, PPD and LPS from 20 HIV-infected and 18 HIV-uninfected individuals.   
 
These results showed that HIV infection did not alter the quantity and quality of 
cytokine responses from monocytes, after stimulation with mycobacterial antigens 
LAM, PPD or whole viable BCG. However, in response to the gram-negative 
bacterial TLR4 ligand LPS, that was included in this study as a control for TLR 
stimulation, cytokine responses from monocytes were significantly impaired in HIV-
infected individuals. This may reflect specific TLR4 stimulation in vivo, from 
circulating products of microbial translocation from the gut, such as LPS (Brenchley 
et al., 2006a), or sensitisation of TLR4 functioning from ongoing activation of the 
innate immune system by HIV-encoded TLR ligands such as ssRNA (Mureith et al., 
2010). Monocyte cytokine responses to TLR stimulation were not associated with 
either HIV viral load, CD4 T cell count or age. 
 
Furthermore, HIV-infected individuals demonstrated significantly lower frequency 
of CD14+ monocytes compared to HIV-uninfected individuals, although this did not 
correlate with HIV viral loads or CD4 T cell counts. Upon stimulation, the frequency 
of CD14+ monocytes and expression levels of CD14 on monocytes was significantly 
reduced in both the groups, in response to LAM, BCG and LPS, likely due to CD14 
shedding. Interestingly, HIV infection differentially altered the degree of CD14 
shedding in response to LAM and LPS.  Whilst there was an inverse correlation 
between the change in CD14 expression and cytokine responses to LAM, LPS and 
BCG in HIV-uninfected individuals, this relationship was disrupted in HIV-infected 
individuals, where no such correlation was observed. For LPS, this is likely 
explained by the enhanced cytokine production observed in HIV infection. However, 
no differences in cytokine production were observed to BCG or LAM stimulation, 
and the dysregulation of CD14 shedding may have implications for monocyte 
functioning not measured in the short-term cytokine assays performed in this study. 
The exact mechanisms of CD14 modulation by HIV require further investigation. 
The results of this study provides further insight into how HIV affects monocyte 
TLR functioning, which may have consequences for innate immune control of M.tb. 
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CHAPTER 4: DISCUSSION 
 
HIV-infected persons are more susceptible to TB, and the reasons for this are not 
fully understood. HIV infection causes depletion of CD4+ T cells, which is thought 
to affect adaptive immunity to M.tb, but in addition, HIV affects the functioning of 
innate cells such as monocytes and macrophages. Monocytes play a key role in 
innate immune defense and are the precursors of macrophages, which are the main 
target cells of M.tb. If the ability of these cells to respond to M.tb is impaired, it 
could contribute to the greater susceptibility of HIV-infected individuals to develop 
TB. One of the ways in which these cells respond to M.tb is through TLR 
stimulation, that leads to the release of pro-inflammatory mediators, triggering innate 
and adaptive immune responses to infection, critical events for the control of M.tb. 
This study sought to investigate whether HIV infection induced functional defects in 
monocytes, impairing their ability to respond to M.tb. The focus was on TLR 
functioning in monocytes, examining whether HIV-infected individuals had altered 
monocyte cytokine responses after TLR stimulation, compared to HIV-uninfected 
individuals.   
 
A multiparameter flow cytometry panel was developed and used to identify 
monocytes and measure their capacity to produce the cytokines IL-1β, IL-6 and 
TNF-α, upon stimulation with mycobacteria-derived TLR ligands. The TLR2 ligand 
LAM, M.tb PPD (which stimulates TLR1, 2, 4 and 6), viable whole BCG (a stimuli 
for TLR1, 2, 4, 6 and 9) were used, as well as LPS, a TLR4 agonist from gram 
negative bacteria, as a positive control. Monocytes form a heterogeneous group of 
cells and three different subsets have been described based on the expression of cell 
surface markers CD14 and CD16 (Ziegler-Heitbrock et al., 2010). The intermediate 
CD14++CD16+ population has been previously demonstrated to expand during 
various infections and inflammations, including HIV and TB (Wong et al., 2012; 
Balboa et al., 2011; Thieblemont et al., 1995; Crowe & Ziegler-Heitbrock, 2010). 
This study, however, was limited to measuring cytokine responses from the classical 
CD14+ monocyte subset, due to technical limitations on the use of the CD16+ 
antibody in the fixed whole blood samples used in this study. Fixation reduced the 
staining intensity of the CD16 marker such that it led to a diminished resolution and 
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lack of discrimination between the different subsets, as discussed in Chapter 2. 
Nonetheless, classical monocytes make up the bulk of the blood monocyte 
population and produced robust cytokine responses when activated with various 
stimuli.  
 
Monocytes varied in their ability to respond to the different TLR stimuli in HIV-
uninfected individuals. BCG was the most potent inducer of pro-inflammatory 
cytokines from monocytes, and responses were highly polyfunctional, producing all 
three cytokines measured, simultaneously. This is not surprising, given that BCG is a 
live whole pathogen composed of many PAMPs that can activate monocytes through 
various pattern recognition receptors. Mycobacterial cell wall components and 
mycobacterial DNA can activate a range of TLRs found on the cell surface and in the 
cytosol of monocytes, such as TLR1, TLR2, TLR4, TLR6 and TLR9 (Kleinnijenhuis 
et al., 2011). In addition to TLR activation, mycobacteria can also activate other 
PRRs found on monocytes, such as the C-type lectin receptors (CLRs) and NOD-like 
receptors (NLRs; as reviewed by Kawai & Akira, 2011). Co-operation between 
TLRs and other PRRs can lead to the activation of various host signaling pathways 
(Ferwerda et al., 2008; as reviewed by Trinchieri & Sher, 2007), which may account 
for the robust response observed with BCG stimulation. In contrast, LAM and LPS 
stimulate innate cells through the single TLRs, TLR2 and TLR4 respectively, and the 
lack of involvement of multiple TLR pathways may explain the lower cytokine 
responses compared to BCG.  
 
Monocytes produced mainly the pro-inflammatory cytokines IL-1β and IL-6, with 
fewer producing TNF-α in response to all the stimuli tested. Previous studies have 
demonstrated that cytokines interact with one another to regulate the production of 
each other, which may help to fine-tune the inflammatory response (Aderka et al., 
1989; Dinarello et al., 1986; Tosato & Jones, 1990). For example, IL-6 has been 
shown to inhibit TNF-α production from monocytes (Aderka et al., 1989; Bailly et 
al., 1990), which may explain the lower levels of TNF-α production from 
monocytes. 
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Considerable heterogeneity was observed among the donors in terms of cytokine 
production by monocytes in response to LAM and LPS. These differences may be 
attributed to a range of factors, such as age, genetic differences, ethnic background 
and history of infections. Even physiological conditions such as physical stress can 
modulate TLR expression and function, whereby after strenuous exercise, TLR 
expression was decreased on CD14+ monocytes, and this may in turn affect cytokine 
production from monocytes (Lancaster et al., 2005). In addition, differences in 
monocyte subset distributions can be influenced by ethnicity and past exposure to 
pathogens (Appleby et al., 2013). Furthermore, polymorphisms in the genes 
encoding TLRs themselves, CD14, TNF and IL-1 (Lin et al., 2007; Louis et al., 
1998; Danis et al., 1994) may also influence the production of cytokines, and were 
found to be related to the inter-individual variability observed among donors. 
Moreover, it has also been demonstrated that age is associated with dysregulation of 
cytokine production, with reduced production of pro-inflammatory cytokines in 
response to LPS stimulation observed in the elderly compared to young individuals 
(Bruunsgaard et al., 1999). Although there was a significant difference in ages 
between the HIV-infected and uninfected groups in this study (median of 32 vs. 22 
years), there was no association between cytokine response and age, likely because 
these are all relatively young individuals. Thus, a range of diverse factors could 
account for the heterogeneity among individuals in their monocyte cytokine 
responses observed in this study.  
 
Comparison of monocyte cytokine responses between the HIV-infected and 
uninfected groups in this study revealed that there were no significant differences in 
the frequency of total cytokine production, individual cytokine production, 
expression levels of cytokines (median fluorescent intensity) as well as 
polyfunctional capacity of monocytes to the mycobacteria or mycobacterial-derived 
stimuli LAM, BCG or PPD. Thus, HIV infection did not lead to defective cytokine 
responses to mycobacterial TLR stimuli. In contrast, the monocyte cytokine response 
to LPS was significantly enhanced in the HIV-infected group compared to uninfected 
individuals. This hyper-responsiveness of monocytes from HIV-infected individuals 
in response to LPS is discussed later in this chapter.   
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Stimulation of monocytes with LAM, BCG and LPS resulted in a reduced frequency 
of CD14+ monocytes in both HIV-infected and uninfected individuals, likely due to 
complete shedding of CD14 from a proportion of monocytes in the population. In 
addition, the expression levels of CD14 on monocytes from both the groups were 
also reduced upon stimulation with these ligands, indicating partial shedding of 
CD14 on some monocytes. Shey et al. (2012) also found markedly lower frequencies 
of CD14+ monocytes upon stimulation with LPS and BCG, and suggested that this 
could be due to either down regulation of CD14, shedding of CD14 or cell death. 
Since all markers in this study were stained intracellularly, any down regulation of 
CD14 in response to stimulation did not compromise the ability to detect monocytes. 
CD14 shedding may therefore explain the reduced CD14+ frequency upon 
stimulation. Measuring sCD14 in the stored supernatants of these monocyte cultures 
would confirm this phenomenon. Shedding of CD14 is induced as a consequence of 
monocyte activation and serves to down modulate CD14 on stimulated monocytes 
(Bazil & Strominger, 1991). This functions as a regulatory mechanism to prevent an 
excessive pro-inflammatory response. The shedding of CD14 from monocytes in 
response to LAM, BCG and LPS is thus likely a mechanism to down modulate CD14 
to prevent excessive cytokine responses. These findings confirm previous studies 
that have demonstrated that besides LPS, other bacterial cell wall constituents such 
as those from gram-positive bacteria and mycobacteria also regulate the CD14 
receptor (as reviewed by Antal-Szalmás, 2000; Landmann et al., 1996; Pugin et al., 
1994).  
 
In contrast to the data on maintenance of cytokine production to mycobacterial 
ligands in HIV infection, a more subtle effect on monocytes was revealed from 
analysis of CD14 regulation. In HIV-uninfected individuals, there was an inverse 
correlation between the degree of CD14 shedding in LAM, LPS and BCG-stimulated 
cultures and cytokine responses to these TLR stimuli. In contrast, this relationship 
was disrupted in HIV-infected individuals, where no such correlation was observed. 
The degree of CD14 shedding from monocytes is important in regulating cytokine 
production upon monocyte activation. However, this association was lost during HIV 
infection. With LPS stimulation (TLR4 response), the relationship between the 
degree of CD14 shedding from monocytes and cytokine production may be impaired 
in HIV infection as a consequence of the enhanced production of cytokines that was 
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observed. However, with LAM stimulation, no cytokine differences were observed. 
The results of this study revealed that the degree of CD14 shedding from monocytes 
was reduced in response to LAM in HIV infection compared to HIV-uninfected 
individuals, leading to dysregulation of the relationship between CD14 shedding by 
monocytes and their ability to produce cytokines. Although this did not affect 
monocyte cytokine responses to TLR stimuli in these individuals as measured by the 
short-term assay (6 h of stimulation) employed in this study, it may be possible that 
there would be longer term functional consequences. Since shedding of CD14 from 
monocytes helps to control the level of monocyte cytokine response, the reduced 
degree of shedding may therefore not be able to modulate the cytokine response well. 
It is speculated that this may have long-term consequences on monocyte activation 
such that the cytokine response in monocytes would not be tightly regulated anymore 
and this may lead to a constant signaling of the TLR2/CD14 pathway, resulting into 
constitutive production of cytokines. Hence, it would be expected that HIV-infected 
individuals would have increased cytokine production to LAM compared to the 
healthy controls. The effects of reduced CD14 shedding on cytokine production may 
only be seen with longer stimulation. Therefore, it can only be speculated that if the 
cytokines were to be measured in a long-term whole blood assay, elevated levels of 
cytokine production from monocytes would be detected in HIV infection in response 
to LAM. It would thus be of interest to perform longer term assays to assess this. 
Hence, the tight regulation in the degree of CD14 shedding is an important 
mechanism for modulating monocyte cytokine responses. HIV may be targeting this 
mechanism leading to the prolonged production of pro-inflammatory cytokines and 
in turn a prolonged inflammation. On the other hand, the CD14 dysregulation 
observed for mycobacterial ligands may affect other monocyte functions or processes 
apart from cytokine production. Since monocytes are key regulators of immune 
response in TB infection, dysfunction of these cells could result in the cell being in a 
constant activated state and this may help to fuel the inflammatory environment in 
the lung that could lead to impaired containment and control of M.tb in HIV co-
infection.  
 
Taken together, these results suggest that during HIV infection, the relationship 
between CD14 loss and monocyte cytokine responses is disrupted. With LPS 
stimulation, this relationship may be disturbed due to the enhanced monocyte 
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cytokine production observed in HIV-infected individuals. However, with LAM 
stimulation, the reduced degree of CD14 loss observed in response to LAM in HIV-
infected individuals might have a long-term consequences on cytokine production or 
other functions of monocytes. Further studies are required to confirm this model and 
assess the relationship between the degree of CD14 shedding and the ability of 
monocytes to produce cytokines. 
 
Stimulation of monocytes with LPS, the non-mycobacterial TLR ligand that was 
included in these studies, revealed interesting results. HIV-infected individuals had 
enhanced monocyte cytokine responses to LPS. This observation extends and 
confirms published data regarding dysregulated LPS responses during HIV infection. 
Enhanced IL-1β, IL-6 and TNF-α levels in supernatants of monocyte cultures from 
HIV-infected individuals after stimulation with LPS from periodontal pathogens has 
been demonstrated (Baqui et al., 2000). Monocytes from healthy individuals 
produced significantly enhanced cytokine responses to LPS after prior stimulation 
with HIV-derived TLR ligands (inactivated HIV, containing single-stranded viral 
RNA; Mureith et al., 2010). HIV may thus have an indirect effect on monocyte 
functioning, whereby sustained stimulation of HIV-responsive TLRs may influence 
how monocytes respond to other TLRs, in a process termed  “TLR cross talk” 
(Chang & Altfeld, 2009). Indeed, this cross talk could explain the enhanced 
monocyte responses to LPS observed in HIV-infected individuals in the present 
study. However, in contrast to these findings, Mir et al. (2012) reported no 
differences in TNF-α production from whole blood monocytes upon LPS stimulation 
between HIV-infected and uninfected individuals. This disparity in results may be 
due to differences in the assays or cohort recruited. The participants recruited in this 
study had CD4 counts ranging from 4 to 833 cells/mm3 and were treatment naïve for 
at least one year. However, our study involved participants that were highly immune 
competent and had CD4 counts greater than 400 cells/mm3 and who have never been 
on ARV treatment before. In addition, this study only used CD14 to characterise 
monocytes by flow cytometry, without including the markers HLA-DR, CD66 and 
CD56 to exclude granulocytes and NK cells, which could have confounded the 
results of the study. 
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In addition to HIV-encoded TLR ligands, it is hypothesised that microbial 
translocation through the gastrointestinal tract allows components of gut bacteria to 
enter the circulation, leading to monocyte activation (Brenchley et al., 2006b).  High 
levels of plasma LPS in HIV-infected individuals were associated with higher levels 
of sCD14, indicating monocyte activation (Brenchley et al., 2006a). Thus, the 
enhanced monocyte responses may be a major contributor to the heightened immune 
activation observed in HIV infection. In fact, plasma levels of sCD14 were 
associated with an increased risk of mortality in HIV infection (Sandler et al., 2011).  
 
In HIV infection, significantly reduced frequencies of CD14+ monocytes were 
observed compared to uninfected individuals, consistent with findings from a 
previous report (Han et al., 2009). The reduced frequency of the CD14+ monocytes 
in HIV-infected individuals may be due to an elevated frequency of the CD16+ 
monocyte subsets that have previously been demonstrated to expand in HIV 
infection, and this may lead to lower proportion of the classical monocytes. 
Determining the absolute counts of the monocyte subsets in blood is therefore 
important to confirm whether the reduced frequency of CD14+ subsets are a result of 
reduced numbers of CD14+ monocytes during HIV infection or due to expansion of 
other monocyte subsets. The reduced frequency of CD14+ monocytes could also be 
due to shedding of CD14 in vivo, in response to circulating LPS in plasma, as a result 
of microbial translocation (Brenchley et al., 2006a).  Triggering of TLR4 may lead to 
CD14 shedding and loss of detection of CD14+ monocytes, as was observed in the 
stimulated cultures in this study. 
 
A number of additional experiments could extend these findings. Since M.tb 
infection occurs in the lungs, examining AMs in HIV co-infection is very important. 
Ongoing studies in our laboratory are examining the effects of HIV co-infection on 
transcriptional profiles of AM. Furthermore, HIV infection may alter the production 
of other cytokines and mediators than the three that were measured by flow 
cytometry in this study; they are unlikely to represent the total cytokine response of 
monocytes to TLR stimulation. Hence, multiplex cytokine assays on culture 
supernatants will be performed in future experiments to examine a wider range of 
cytokines, chemokines and other mediators released in response to mycobacterial 
TLR stimuli, such as IL-12, IL-10, NO and MCP-1. HIV infection may also affect 
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the function of the other monocyte subsets that this study was unable to characterise 
(those expressing CD16). Hence, it would be of interest to determine whether HIV 
alters TLR functioning and cytokine production from these subsets in response to 
mycobacteria-derived stimuli, which could be performed in PBMC that were stored 
from these participants. 
 
Summary 
Collectively, the data presented in this thesis demonstrate that monocytes from HIV-
infected individuals released pro-inflammatory cytokines and preserved their innate 
ability to respond to mycobacterial-derived stimuli. In contrast, there was enhanced 
responsiveness of monocytes to LPS stimulation during HIV infection, that may 
reflect specific TLR4 cross talk from ongoing activation of the innate immune 
system by HIV-encoded TLR ligands or by the circulating products of microbial 
translocation from the gut.  The results of this study also provide evidence for CD14 
dysregulation in response to mycobacterial LAM in HIV-infected individuals, and 
propose a model for how HIV differentially affects TLR2 and TLR4 responses. The 
precise mechanism responsible for the CD14 dysregulation is yet to be elucidated. 
These data provide a framework for future experiments and an insight into how HIV 
affects innate immunity to M.tb, which is important for a better understanding of 
how a protective immune response develops against M.tb. This could improve our 
understanding of immunity against TB by highlighting deficiencies that lead to 
disease in the context of HIV infection and may ultimately lead to better TB vaccines 
and immunotherapies, thereby decreasing morbidity and mortality for both diseases. 
In addition, this study complements ongoing studies in our laboratory that are 
investigating how HIV affects both adaptive and innate immunity to M.tb in the 
lungs of HIV-infected individuals with latent TB infection. These studies promise to 
provide a more complete picture of how HIV co-infection affects immunity to M.tb. 
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Future work 
Apart from the additional studies already suggested in this discussion, other avenues 
for further research include the following: 
• The effect of HIV on the expression of M.tb-responsive TLRs on monocytes 
could be investigated by flow cytometry on the archived samples stored from the 
study. This would allow us to address whether HIV infection leads to altered 
expression of TLRs on monocytes that would affect how these cells respond to 
M.tb. 
• In addition to TLRs, there are additional pattern recognition receptors on and 
within monocytes and AM that M.tb can stimulate, such as NOD-like receptors, 
CLRs (MR, DC-SIGN) and scavenger receptors. These receptors as well as 
downstream adaptor proteins and molecules (MyD88) all represent potential 
avenues for further research using archived clinical material that have been 
collected and stored in this study. 
• Studies could also be performed to explore how HIV affects other monocyte 
functions, such as their differentiation potential into macrophages upon 
recruitment to the site of infection. In vitro studies could explore how the 
inflammatory environment of the lung during HIV-infection affects monocyte 
differentiation, by culturing monocytes from HIV-uninfected individuals to BAL 
fluid that we have collected from HIV-infected individuals and then determining 
how the macrophages subsequently respond to M.tb. 
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